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I. INTRODUCTION 
For a long time many research groups have spent much effort in gaining control 
over human cytomegalovirus (HCMV) disease. HCMV infection is usually 
asymptomatic and without severe problems in healthy individuals. However, in 
immunocompromised and immunosuppressed hosts (e.g. infected newborns, 
HIV-patients, and transplant recipients) HCMV may cause lifelong problems and 
require expensive treatment with harmful secondary effects. 
A large number of research groups focused on the development of a vaccine to 
successfully prevent HCMV diseases by following different approaches (e.g. 
live-attenuated HCMV vaccines, DNA vaccines, virus-like particle vaccines 
(VLP), peptide vaccines, and different viral vector vaccines). Although there are 
some HCMV vaccine candidates that already entered preclinical studies and 
clinical trials, not a single efficient vaccine has been generated and licensed until 
now.  
Within the viral vector vaccines, Modified Vaccinia Virus Ankara (MVA) is one of 
the most promising candidates due to its replication deficiency in human cells but 
efficient expression of recombinant proteins encoded by heterologous genes. In 
addition, MVA induces both cellular and humoral immune responses. Thus, MVA 
is meeting another important prerequisite for a satisfying vaccine.  
This study evaluates an HCMV vaccine candidate (MVA-pp65/IE-1) based on 
MVA that has recently been constructed in our laboratory. MVA-pp65/IE-1 
encoding a fusion gene of the full-length HCMV pp65 and a modified IE-1 cDNA 
is characterized genetically and immunologically. Recombinant MVA-infected 
CD40 B cells are established as valuable tool for immunological characterization 
of recombinant HCMV-MVAs and used to show successful propagation and 
functionality of HCMV-specific T cells within PBMC by MVA-pp65/IE-1. 
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II. LITERATURE REVIEW 
1. Modified Vaccinia Virus Ankara (MVA) 
The host-range restricted Modified Vaccinia Virus Ankara (MVA) is an attenuated 
strain of vaccinia virus that emerged after more than 516 strict passages of 
Chorioallantoic Vaccinia Virus Ankara (CVA) in primary chicken embryo 
fibroblasts (CEF) (MAYR & MUNZ, 1964; MAYR et al., 1975). MVA lost 
approximately 15% of CVA’s total genome including the six major deletion sites 
(Fig. 4) as well as numerous small deletions and mutations (MEYER et al., 1991; 
ANTOINE et al., 1998). As a result, MVA and CVA have distinct differences in 
cell culture and infectivity (MAYR et al., 1978). Although the genome between 
parental CVA and MVA changed substantially, the genome of MVA was 
considered as stable after examination of different passages of MVA (MAYR et 
al., 1978). Despite MVA’s inability to replicate in mammalian cells, it still retains 
infectivity of them (MEYER et al., 1991; CARROLL & MOSS, 1997; 
BLANCHARD et al., 1998; DREXLER et al., 1998). 
1.1. MVA as vaccine platform 
Vector and vaccine production is convenient, including established protocols for 
the generation of recombinant vaccinia viruses (BRODER & EARL, 1999). 
Vaccinia viruses (VACV) have been established as a valuable tool for vaccination 
since 1982, for its ability to express foreign genes (MACKETT et al., 1982; 
PANICALI & PAOLETTI, 1982). Further advantages of VACV are their lack of 
persistence, their large DNA capacity, their replication cycle which completely 
takes place outside the cellular nucleus, and their high immunogenicity as 
vaccines (MOSS, 1996). Moreover, all orthopoxviruses including VACV have 
many virulence factors that interact with components of the innate immune 
system. Though, recombinant VACV are able to induce a strong adaptive 
immune response, both the humoral and cellular, against heterologous genes 
they encode (BENNINK et al., 1984; SMITH et al., 2013). 
Despite of the multitude of advantages, VACV may cause life-threatening 
complications (postvaccinal encephalitis, vaccinia necrosum, and eczema 
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vaccinatum) and side effects (fever, pruritus, lymphadenopathy, muscle aches, 
and nausea) which were observed during the eradication campaign against the 
variola virus (LANE et al., 1969; KENNEDY et al., 2009).  
In order to eliminate these complications and side effects, efforts were made to 
develop VACV with reduced virulence. Approaches included the insertion of 
lymphokine, the deletion of genes associated with virulence, and the 
development of VACV strains that were attenuated by passaging, such as 
NYVAC or MVA, which both partly lost their virulence (MOSS, 1991, 1996). Since 
the 1990s, MVA has been shown to be a particularly useful vaccine platform 
(SUTTER & MOSS, 1992). While the replication of NYVAC in human cells is 
already blocked at an early stage (TARTAGLIA et al., 1992; PAOLETTI, 1996), 
MVA’s early and late gene expression is not impaired; instead virion assembly is 
blocked (SUTTER & MOSS, 1992). Hence, MVA offers an advantage over 
NYVAC as a vaccine platform. 
The safety of MVA has already been tested in over 100,000 individuals during a 
smallpox vaccination program in Bavaria with high acceptance rates and 
negligible side effects (STICKL et al., 1974; MAYR et al., 1978). Since 2013, 
MVA is a licensed smallpox vaccine in Europe and Canada (EUROPEAN 
MEDICINES AGENCY, 2013). MVA was tested in immunosuppressed monkeys 
without severe side effects, providing evidence that immunocompromised 
individuals can be vaccinated with recombinant MVA vaccines to achieve 
protection against various diseases (STITTELAAR et al., 2001). It has been over 
20 years since the first recombinant MVA vaccines were observed to successfully 
induce adaptive immune responses in the form of CD8 T cells and antibodies, 
and provide protection against viral challenge infections in animal models 
(SUTTER et al., 1994; HIRSCH et al., 1996).  
Compared to replication competent VACV, MVA is able to trigger immune 
responses due to different mechanisms. MVA lacks several functional viral 
receptors for host cytokines including CC chemokines, IFN- / , IFN- , and TNF 
that are involved in viral-host interaction and immune modulation (BLANCHARD 
et al., 1998). Furthermore, it has been shown that only MVA, not replication 
competent VACV, is able to induce early recruitment of leukocytes and the 
production of interferon and other chemokines (e.g. CCL2) (WAIBLER et al., 
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2007; LEHMANN et al., 2009). Moreover, MVA was equally or better able to 
induce the immune system against their recombinant foreign gene sequences, 
whereas immune responses against MVA’s own antigens were lower compared 
to replication competent VACV Western Reserve (WR) (RAMIREZ et al., 2000). 
Overall, MVA is a safe and immunogenic vector vaccine platform that efficiently 
produces recombinant proteins and stimulates the immune system without 
requiring any further adjuvants (KREIJTZ et al., 2013). 
1.2. MVA in preclinical studies and clinical use  
In recent years, the MVA vector has become increasingly important for the 
development of vaccines against various emerging infectious diseases (e.g. 
influenza, West Nile, chikungunya), diseases caused by intracellular pathogens 
that are very difficult to control (e.g. AIDS, tuberculosis, malaria), and multiple 
tumors (e.g. cervical cancer, melanoma) (GILBERT, 2013; KREIJTZ et al., 2013; 
VOLZ & SUTTER, 2013).  
Recombinant MVA vaccines against various infectious agents have been 
successfully evaluated in different animal models for being safe and 
immunogenic (YUE et al., 2008; KREIJTZ et al., 2010; VAN DEN DOEL et al., 
2014). Moreover, different recombinant MVA vaccine candidates provided 
protection against otherwise lethal challenges in mice (KREIJTZ et al., 2007; 
KREIJTZ et al., 2009; VAN DEN DOEL et al., 2014).  
Tumor therapy is another important application of MVA. First, it has been shown 
that tumors associated with human papillomavirus were no longer able to grow in 
mice after MVA vaccination (VALDEZ GRAHAM et al., 2000) and in a clinical 
phase I-trial the growth of such tumors was transiently stabilized (ROCHLITZ et 
al., 2003). In both studies no severe side effects were detectable when MVA was 
used. Second, when comparing MVA to the replication competent VACV WR in 
melanoma cells, only MVA was able to induce an effectual immune response of 
bystander dendritic cells (DCs) (GREINER et al., 2006). Third, clinical trials 
showed that vaccination with recombinant MVA encoding for papillomavirus 
antigens resulted in immunogenicity detected by measuring specific antibodies 
and cytotoxic responses against papilloma-transformed cells (ALBARRAN et al., 
2007). Recently, a phase III clinical trial of the same recombinant MVA encoding 
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papilloma antigens showed promising results in containment of mucosal lesions 
caused by papilloma virus (ROSALES et al., 2014).  
Due to established generation procedures, recombinant MVA vaccines can be 
targeted against rapidly evolving or emerging infectious diseases, e.g. influenza 
or the Middle East respiratory syndrome coronavirus (MERS-CoV). 
MVA-NP-M1, a promising recombinant MVA vaccine candidate against influenza, 
was successfully evaluated in three different clinical trials. First, the vaccine was 
confirmed as safe and immunogenic (BERTHOUD et al., 2011). In a second 
study, volunteers were challenged with influenza A/Wisconsin/67/2005 after 
immunization using MVA-NP-M1, which showed that virus shedding and signs of 
illness were reduced (LILLIE et al., 2012). Further, MVA-NP-M1 was tested in 
patients over age 50 to address those people that would benefit most from the 
development of a vaccine against influenza. In all trials, the MVA vaccine 
candidate showed no severe side effects and activation of T cells could be 
observed (ANTROBUS et al., 2012).  
It has been verified that MVA can be used as vector vaccine platform against 
MERS-CoV, a viral disease that was first described in 2012 (ZAKI et al., 2012). In 
2013, a promising vaccine candidate based on MVA (MVA-MERS-S) was 
characterized in vivo and was proven to provide protection against MERS-CoV 
challenge in mice in 2015 (SONG et al., 2013; VOLZ et al., 2015). Most recently, 
it was even possible to show that the excretion of infectious viruses was 
significantly reduced after immunization of dromedaries with MVA-MERS-S 
followed by MERS-CoV challenge (HAAGMANS et al., 2016). Dromedaries are 
believed to play a role as a virus reservoir and transmission vector (REUSKEN et 
al., 2015), hence their immunization might curb epidemics and prevent infection 
of humans. 
As these examples show, recombinant MVA viruses have been successfully 
tested in various preclinical and clinical studies as vaccines against various 
diseases. This progress encourages further investigation and usage of multiple 
MVA-based vaccines against infectious diseases that are emerging or have been 
difficult to control through other means.  
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2. Human Cytomegalovirus (HCMV) 
Human Cytomegalovirus (HCMV) belongs to the subfamily of -Herpesvirinae 
and has the largest genome among all herpesviruses, roughly 230 kb encoding 
approximately 165 genes (DAVISON et al., 2003). Among the human population 
in Europe, the seroprevalence of HCMV ranges between 30 and 90% increasing 
with age and differing in geography (LUDWIG & HENGEL, 2009). Differences in 
prevalence rates of HCMV throughout the world depend on socioeconomic as 
well as geographical factors (CANNON et al., 2010).  
The HCMV virion consists of a double-stranded linear DNA genome in an 
icosahedral nucleocapsid surrounded by the proteinaceous tegument (Fig. 1). 
The tegument compartment contains the majority of the virion proteins, including 
the lower matrix phosphoprotein 65 (pp65), a major target of T cell responses 
(SYLWESTER et al., 2005).  
Fig. 1: Structure of HCMV virion. Image obtained from https://siinfekl.files.wordpress.
com/2014/12/hcmv-virion.jpg by courtesy of Dr. Marko Reschke, Berlin, Germany.
 
The DNA core and tegument are enclosed by a lipid envelope that contains 
several different viral glycoproteins (gB, gH, gL, gM, gN, gO) that form complexes 
known as glycoprotein complex I, II, and III (Fig. 1) which are involved in virion 
maturation, cell attachment, and penetration (MOCARSKI et al., 2013). The 
glycoprotein complexes display major targets of antibody responses. For 
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example, neutralizing antibodies during HCMV infection are directed against gB 
(BRITT et al., 1990) and a pentameric complex consisting of gH, gL, and three 
additional glycoproteins (FOUTS et al., 2012; FREED et al., 2013). HCMV is 
highly species-specific and can be transmitted not only through various body 
fluids, most commonly saliva and urine, but also through solid-organ 
transplantation (SOT) or hematopoietic stem cell transplantation (HSCT) (SIA & 
PATEL, 2000). 
A cascade of immediate-early, early, and late gene expression sequentially 
occurs during HCMV infection (STINSKI, 1978). The immediate-early 1 (IE-1) 
protein has been recognized as another major target of T cell responses against 
HCMV (BORYSIEWICZ et al., 1988; SYLWESTER et al., 2005). HCMV requires 
gB and gH/gL to enter fibroblasts and the gH/gL-pentamer complex composed of 
gH, gL, UL128, UL130, and UL131A for penetration of epithelial/endothelial cells 
(WUSSOW et al., 2014).  
Primary HCMV infection in healthy individuals is usually asymptomatic and leads 
to a lifelong latency without severe problems, as long as the immune system is 
unaffected. However, primary infection or reactivation of HCMV may cause 
severe to life-threatening problems in newborns and immunocompromised hosts, 
such as mental retardation, hearing loss, and visual impairment in newborns 
(PASS et al., 1980; CONBOY et al., 1987), retinitis in HIV patients (JABS et al., 
1989), as well as hepatitis, pneumonia, and gastrointestinal diseases in 
transplant recipients (HUMAR & MICHAELS, 2006). Furthermore, HCMV 
infection strongly influences secondary infection outbreaks and mortality rates 
after transplantation (BOECKH & LJUNGMAN, 2009). HCMV is the leading 
non-genetic cause of congenital malformations in developed countries  
(HAMILTON et al., 2014) and the leading viral pathogen in transplantation. Thus, 
it is highly relevant to focus on its treatment and prevention.  
2.1. Therapeutic strategies  
Different therapeutic strategies are pursued to control HCMV diseases, including 
medication with antiviral drugs, passive immunization with immunoglobulins, or 
adoptive transfer of cytotoxic-specific T cells (CROUGH & KHANNA, 2009). 
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2.1.1. Antiviral drugs 
Four antiviral drugs (Ganciclovir, Valganciclovir, Foscarnet, and Cidofovir) are 
currently approved for HCMV treatment and prevention; all of them, however, 
may cause major toxicity. Thus, their administration requires limitation and is only 
advised in patients that are of high risk to develop life threatening HCMV 
diseases (MOCARSKI et al., 2013). Treatment with Ganciclovir during the first 
100 days after transplantation had a positive influence on the survival rate of 
transplant recipients. However, an increase of late HCMV disease was observed 
(GOODRICH et al., 1991; LI et al., 1994). Additionally, mutations in HCMV’s 
phosphotransferase-gene (UL97) and polymerase gene (UL54) may give rise to 
resistance to each of these antiviral agents (LURAIN & CHOU, 2010). 
Therefore, other drugs like Maribavir have been currently developed and 
evaluated in clinical trials (MARTY et al., 2011; WINSTON et al., 2012), but none 
reached market authorization, yet. Although Maribavir was not completely 
successful in preventing HCMV disease in these trials, it was effectively used in 
one heart transplant recipient to gain control of otherwise drug-resistant 
cytomegalovirus colitis (ZEGRI REIRIZ et al., 2015).  
2.1.2. Immunoglobulins 
In some clinical settings, SOT recipients received HCMV-specific hyperimmune 
globulin, which correlated with increased survival rates (FALAGAS et al., 1997) 
and reduced diseases associated with HCMV (SNYDMAN et al., 1987).  
In contrast, benefit of globulin application in the case of HSCT recipients is less 
clear. Some analyses claimed beneficial outcomes (MESSORI et al., 1994; 
SCHOPPEL et al., 1998), whereas others demonstrated no or even a negative 
correlation between immunoglobulin administration and outcome (MUNOZ et al., 
2001; LUDWIG et al., 2006). Even for pregnant women, where the role of 
HCMV-specific antibodies is regarded as crucial, no decrease in transmission 
rates of HCMV to the child after administration of globulins could be attested 
(REVELLO et al., 2014). 
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2.1.3. Adoptive immunotherapy of HCMV 
The transfer of cytotoxic-specific T cells is widely acknowledged as beneficial. 
The role of T cells is considered very important in the control of HCMV disease, 
since its incidence is inversely correlated to the reconstitution of cellular immunity 
after allogeneic bone marrow transplantation (QUINNAN et al., 1982; REUSSER 
et al., 1991). In complementary studies, immunosuppressed mice showed 
protection against MCMV challenge after transfer of MCMV-specific T cells 
(REDDEHASE et al., 1985; MUTTER et al., 1988). In line with these results, stem 
cell donor-derived HCMV-specific T cells were successfully generated and 
transferred to transplant patients to prevent HCMV disease (RIDDELL et al., 
1992; WALTER et al., 1995). 
Until now, there are two different approaches for adoptive transfer of 
cytotoxic-specific T cells: in vitro stimulation or direct enrichment of 
HCMV-specific T cells (CROUGH & KHANNA, 2009). HCMV-specific T cells can 
be generated by infecting autologous fibroblasts with HCMV viruses (e.g. AD169) 
for stimulation of PBMC (RIDDELL et al., 1992), by infection of PBMC with 
recombinant viruses encoding HCMV antigens (RIST et al., 2005), or by 
co-cultivation with HCMV-antigen-pulsed DCs (PEGGS et al., 2001; 
MICKLETHWAITE et al., 2007). The enrichment of HCMV-specific T cells in 
PBMC can be performed by MHC/peptide tetramer staining followed by direct 
infusion of these cells (COBBOLD et al., 2005). 
2.2. Prevention 
It is often neglected that basic precautions can be effective in preventing 
transmission of HCMV infection. Hygiene (e.g. hand washing) and proper 
protective equipment (e.g. gloves, condoms) decreases HCMV delivery by saliva 
and sexual contact (ROBAIN et al., 1998; ADLER et al., 2004). However, since 
the incidence of infection is high and infectivity of carriers is difficult to predict, the 
development of a protective vaccine remains an urgent necessity. 
In particular, vaccination of HCMV-negative women before conception is likely to 
reduce or prevent infection of newborns during pregnancy. Moreover, recipients 
of both single organs (SO) and hematopoietic stem cells (HSC) would benefit 
from a vaccine against HCMV. In patients with HCMV-positive serostatus prior to 
stem cell transplantation, the risk of HCMV disease is higher when the donor is 
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seronegative (MOCARSKI et al., 2013) because in this case HCMV-specific 
immunity is not co-transferred during stem cell transplantation. Thus, it might be 
most beneficial to vaccinate the donor before transplantation. A seronegative 
patient receiving an organ from a seropositive donor is at the highest risk to 
develop HCMV disease during immunosuppressive therapy (MOCARSKI et al., 
2013). Here, the vaccination of the recipient before transplantation would be 
most favorable.  
A more extensive approach would be the immunization of the whole population 
that might lead to decreases in HCMV infections and reactivations during 
transplantations and pregnancies due to the minimization of HCMV 
seroprevalence (KRAUSE et al., 2013). 
2.2.1. Vaccination to prevent HCMV disease 
Research on the development of a vaccine against HCMV has been conducted 
for more than 40 years. Many groups are working on this subject by following 
different kinds of strategies. The type of vaccines that have been generated to 
prevent HCMV disease can be split into two main groups: 1) live-attenuated 
HCMV vaccines derived from different HCMV strains and 2) vaccines that include 
only immunogenic parts of the HCMV virus. The latter can be grouped into DNA 
vaccines (WLOCH et al., 2008), virus-like particle (VLP) vaccines (PEPPERL et 
al., 2000), peptide vaccines (ZHONG et al., 2008), and different viral vector 
vaccines (WANG et al., 2004; REAP et al., 2007; WILSON et al., 2008). Although 
some vaccine candidates are in clinical trials, none of them completely prevent 
HCMV disease.  
The first vaccines were based on attenuated HCMV viruses which presented 
different antigens that induced antibodies and cytotoxic T cells. The attenuated 
HCMV viruses AD169 and Towne 125 strain were tested in clinical trials for their 
safety and immunogenicity (ELEK & STERN, 1974; PLOTKIN et al., 1976). Both 
viruses induced neutralizing antibodies when being applied in different infection 
routes (subcutaneous and intranasal). Unfortunately, antibody responses 
dropped over time and complete protection from HCMV infection was not 
achieved. In consequence, Towne 125 strain was modified to increase its 
immunogenicity by designing a chimeric virus composed of Towne 125 and the 
unattenuated HCMV strain Toledo which is not yet a suitable vaccine 
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(HEINEMAN et al., 2006). A potential reason why the Towne 125 strain failed in 
neutralizing virus-infected epithelial cells (CUI et al., 2008) are mutations in the 
viral UL128-131 locus that probably appeared during passaging on fibroblasts 
(PRICHARD et al., 2001; DARGAN et al., 2010). This locus forms the pentameric 
complex together with the glycoproteins gH and gL and plays a central role 
during HCMV infection of epithelial cells (RYCKMAN et al., 2008; LOUGHNEY et 
al., 2015).  
Vaccine development is not only focused on attenuated HCMV live viruses, but 
also on heterologous vaccines based on immunogenic HCMV antigens. The first 
subunit vaccine against HCMV consisted of the HCMV gB and MF59, an 
oil-in-water adjuvant. This vaccine was able to induce only short term gB-specific 
antibodies in HCMV seronegative donors (FREY et al., 1999; PASS et al., 1999) 
that failed in neutralizing virus-infected epithelial cells. One reason might be that 
these antibodies cannot prevent viral entry to endothelial and epithelial cells (CUI 
et al., 2008; GERNA et al., 2008; MACAGNO et al., 2010). In 2012, Fouts et al. 
observed that antibodies against the pentamer-complex and not antibodies 
against gB are an important target for neutralizing virus-infected epithelial cells 
(FOUTS et al., 2012). 
Moreover, clinical trials using DNA vaccines showed poor immunogenicity and 
could not prevent HCMV disease (DONNELLY et al., 1997). However, an 
increase in immunogenicity was partly achieved by combining DNA vaccines with 
other vector platforms such as MVA (GIL et al., 2013). 
Peptide based vaccines have been tested in a preclinical study using transgenic 
mice. In this examination the peptides themselves - without any adjuvants - were 
able to induce immune responses against HCMV (LA ROSA et al., 2002). In a 
human clinical trial phase Ib, adjuvant was necessary to obtain a response to 
peptide vaccine, but this response was limited to HCMV-positive probands (LA 
ROSA et al., 2012).  
In contrast to the aforementioned vaccines that did not successfully prevent 
HCMV disease or were not shown to be sufficiently immunogenic, viral 
vector-based vaccines appear to be a more promising approach. For example, 
two alphavirus replicon vaccines encoding either a soluble version of the 
II. Literature Review     13 
HCMV-gB or a fusion of the complete pp65 and IE-1 gene sequences were 
tested simultaneously in a clinical trial phase I that activated neutralizing 
antibodies, CD4, and CD8 T cells (BERNSTEIN et al., 2009). However, a vaccine 
based on canary pox (ALVAC) failed to induce neutralizing activities and 
HCMV-specific IgGs. This was not surprising, as they again encoded for the 
HCMV gB protein that also failed to prevent HCMV disease in all previous 
vaccine attempts (ADLER et al., 1999). In contrast, a substantial induction of 
cell-mediated responses was detectable in a study using the ALVAC vector 
encoding for pp65 instead of gB (BERENCSI et al., 2001). 
Another viral vector-based HCMV vaccine approach uses MVA as a vaccine 
platform. Both vaccine candidates encoding either pp65 or exon 4 of IE-1 (WANG 
et al., 2004) and a further HCMV-MVA encoding pp65 and exon 4 of IE-1 
separately, have been successfully tested in preclinical studies (WANG et al., 
2007). 
As these experiences show, the development of an HCMV vaccine appeared to 
be difficult and suffered from drawbacks. However, recent progress in research, 
in particular regarding HCMV immunity, has improved the chances to reach this 
goal in the future.  
3. The immune system 
The human immune system is composed of various cellular and molecular 
constituents that are able to defend the human body against invading pathogens 
such as viruses, bacteria, parasites, and fungi. The skin and mucous membranes 
form a first barrier for pathogens. If these physical barriers are bypassed, the 
innate immunity, consisting of various effector cells (e.g. macrophages, NK cells) 
and molecules, is activated immediately and combats the pathogens. In addition, 
the adaptive immune system is able to recognize and contain individual 
pathogens more specifically by either a humoral or cellular pathway. B cells play 
a central role in the humoral immune system and directly detect pathogenic 
particles. After contact with antigen, B cells differentiate to plasma cells that 
secrete specific antibodies into blood and body fluids, where they circulate until 
they interact with specific antigenic structures (epitopes) of pathogens. 
Thereafter, these antigen-antibody complexes are cleared by other immune cells, 
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e.g. macrophages. In contrast, T cells – one major component of the cellular 
immune system – recognize infected cells that present peptides from the 
pathogen’s proteins on specific cellular surface molecules. The first production of 
specific B and T cell responses usually takes 1-2 weeks after a pathogen enters 
the human body. After that, clonally expanded memory cells are maintained in 
the body, which ensures that the immune response to reinfection or reactivation 
is even faster (MURPHY et al., 2008). 
3.1. T cells  
T cells originate from pluripotent HSC of the bone marrow. T cell precursors 
move to the thymus where they mature into two distinct T cell lineages: :  or 
:  T cells. A small fraction mature into the latter type of T cells whose purpose is 
not fully understood. However, recent research illustrated that :  T cells 
recognize phospholipids, soluble proteins, as well as smaller peptides (BORN et 
al., 2013). The majority of T cells end up with a T cell receptor (TCR) consisting 
of the two chains  and  that are encoded at respective gene clusters composed 
of different gene segments (V, D, J). These are rearranged and joined during 
T cell maturation, resulting in a large variety of possible TCRs (DAVIS & 
BJORKMAN, 1988) that recognize a distinct epitope sequence on antigens. A 
mature T cell generally carries one TCR, which defines its specificity, and the 
mature T cell repertoire contains millions of specificities.  
T cells can be further distinguished by the appearance of different surface 
co-receptors, either cluster of differentiation 8 (CD8) or 4 (CD4). The major 
function of cytotoxic CD8 T cells is to mediate cell death of infected cells by 
secreting granzymes, perforin, and cytokines (e.g. IFN- , TNF) (KAECH & CUI, 
2012). Native CD4 T cells mostly fulfill auxiliary functions for other immune cells 
and can be differentiated into five effector subsets (TH1, TH2, TH17, TFH, and Treg) 
that vary in the presence of different transcription factors and the proportions of 
cytokines they produce including IL-4, IL-5, IL-10, and IFN-  (GEGINAT et al., 
2014).  
Only a minor portion of premature T cells become MHC-restricted and 
self-tolerant mature T cells, whereas the majority are deleted in the thymus 
during maturation, because they do not fulfill all necessary requirements (e.g. 
appropriate receptor specificities) (MURPHY et al., 2008). 
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3.2. Antigen presentation  
Cells present small protein fragments (peptides) on their cellular surface by 
loading them onto glycoprotein molecules known as major histocompatibility 
complex (MHC) class I or II. Almost every human cell, except for human blood 
cells, present peptide-loaded MHC class I molecules on their cellular surface to 
CD8 T cells. Healthy cells only load self-peptides on MHC class I molecules, 
while infected cells additionally present peptides derived from their internal 
pathogen. In contrast, MHC class II molecules interact with CD4 T cells. They are 
exclusively present on specialized immune cells, named antigen presenting cells 
(APCs), which include B cells, DCs, endothelia cells, macrophages, and 
monocytes (GERMAIN, 1994).  
3.2.1. Structure of MHC class I and II molecules 
MHC class I molecules consist of one -chain composed of 3 domains ( 1- 3) 
and a 2-microglobulin (Fig. 2). The -chain is encoded by one of three major 
genes named human leucocyte antigen (HLA-A, HLA-B, and HLA-C) that are 
located on chromosome six in humans. Polymorphism and allelic variations of 
these genes result in a broad range of different -chains. The peptide-binding 
cleft of MHC class I molecules is formed by the 1 and 2 domain and allows for 
the binding of peptides that are generally 8-11 amino acids (aa) long, most often 
9 aa (Fig. 2) (MURPHY et al., 2008).  
peptide-binding
cleft
1
2
1
2
peptide-binding
cleft
12
3
2-microglobulin
MHC class I MHC class II
cell membrane
Fig. 2: Structure of MHC class I
and MHC class II molecules.
Both molecules consists of an 
and  domain. MHC class I
molecules have  three covalently
bound parts of the  chain (1-3),
one transmembrane region with
cytosolic region and an
2-microglobulin that are
noncovalently bound. Both chains
( and ) of MHC class II
molecules have their own
transmembrane region with
cytosolic region. Contrary to
MHC-I, the 1 and 1 subdomains
of MHC-II are noncovalently linked
to each other (Modified according
to Murphy, 2008).
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MHC class II molecules consist of one  and one  chain that are both anchored 
in the cell membrane (GERMAIN, 1994). Similar to MHC class I molecules, MHC 
class II molecules are encoded by polymorphic genes (in humans HLA-DR, 
HLA-DQ, and HLA-DP) (NEEFJES et al., 2011). Here, the 1 and 1 domains 
form the peptide-binding cleft which differs slightly to its MHC class I counterpart 
(Fig. 2) by allowing longer aa-sequences (13-17 aa) to be loaded and presented 
(MURPHY et al., 2008).  
3.2.2. Peptide loading on MHC class I and MHC class II molecules 
In healthy cells, proteins are constantly being cleaved into small peptides by the 
proteasome, a protease complex in the cytoplasm. The evolving peptides reach 
the endoplasmic reticulum (ER) by a heterodimeric transporter associated with 
antigen processing (TAP) composed of two subunits (TAP-1 and TAP-2) 
(CRESSWELL, 2000). Peptides remaining in the cytoplasm are degraded within 
seconds if they are not bound to TAP-1 or -2 (REITS et al., 2003).  
Inside the ER, the partly-folded MHC class I molecules are stabilized by different 
chaperons (calreticulin, ERp57, and tapasin). Together with TAP, they form the 
peptide-loading complex that is essential for peptide-loading of MHC class I 
molecules (CRESSWELL et al., 1999). Without peptides, MHC molecules are not 
stable and remain in their partly-folded state inside of the ER (CRESSWELL, 
2000). Only the complete peptide/MHC class I complex is transported to the 
plasma membrane and recognized by epitope-specific CD8 T cells. Peptides not 
suited for the peptide-binding cleft of MHC class I molecules fail to bind 
(MURPHY et al., 2008). These peptides are either cut by ER amino peptidases 
(ERAP1 and ERAP2) to enable binding to MHC class I molecules or released 
into the cytoplasm, where they are degraded (SAVEANU et al., 2005).  
Peptide loading of MHC class II molecules occurs in the MHC class II 
compartment (MIIC). Previously, the dimerization of the  and  chain takes 
place in the ER and is stabilized by the chaperon invariant chain (li) that blocks 
the MHC class II-binding groove for antigenic peptides (NEEFJES et al., 2011). 
The li-MHC class II complex enters a late endosome to form the MIIC (BRYANT 
& PLOEGH, 2004). Within the MIIC, the invariant chain is cleaved by cysteine 
proteases until only a short peptide, class II-associated li peptide (CLIP), remains 
inside the binding groove of the MHC class II molecule (HONEY & RUDENSKY, 
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2003). In humans, MHC class II molecules interact with the chaperone-like 
HLA-DM (in B cells additionally with HLA-DO) that support the replacement of 
CLIP by appropriate peptides within the MIIC (BROCKE et al., 2002). The 
complete peptide/MHC class II complex is displayed at the cellular membrane 
and recognized by peptide-specific CD4 T cells (NEEFJES et al., 2011). 
MHC class I molecules usually embed peptides of various antigens that are 
present in the cytoplasm including intracellular pathogens, while MHC class II 
molecules are mainly loaded with exogenous antigens such as specific 
pathogens (e.g. bacteria, parasites) that are taken up and reach the MIIC through 
vesicular transport (MURPHY et al., 2008). Apart from this, APCs are capable of 
loading pathogenic peptides on their MHC class I molecules which is known as 
cross-presentation (JOFFRE et al., 2012). Furthermore, MHC class II molecules 
load not only peptides from pathogens but also endogenous antigens including 
cellular peptides (GROMME et al., 1999; CROTZER & BLUM, 2010). 
3.3. HCMV and the cellular immune response 
During transplantation, HCMV disease usually occurs once the cellular immune 
response is suppressed. Thus, it is very likely that parts of the cellular immune 
system play a crucial role in controlling HCMV.  
This goes in parallel with observations seen in bone marrow transplants where 
the recovery of cytotoxic T cells was strongly correlated with the prevention of 
HCMV diseases (REUSSER et al., 1991; BARRON et al., 2009). In addition, 
adoptive transfer of HCMV-specific T cells prevented transplant patients from 
HCMV disease (RIDDELL et al., 1992; WALTER et al., 1995). Moreover, in renal 
transplant recipients, a large increase in numbers of HCMV-specific T cells was 
detectable only in those that were able to control HCMV disease (RADHA et al., 
2005).  
Studies using the murine animal model provide experimental in vivo proof of an 
important role of CD8 T cells concerning CMV infection (REDDEHASE et al., 
1985; POLIC et al., 1998). Furthermore, HCMV diseases in immunosuppressed 
transplant recipients were more frequent in cases where the reconstitution of 
CD8 T cells was either undetectable or delayed (REUSSER et al., 1991; 
BOECKH et al., 2003).  
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An important role of CD4 T cells is also implied by a majority of studies. The 
murine model initially suggested that CD4 T cells are not crucial, since 
CD8 T cells alone were able to inhibit severe CMV infections (REDDEHASE et 
al., 1987; REDDEHASE et al., 1988). In contrast, more recent studies argued 
that the presence of CD4 T cells and NK cells had a positive impact in the murine 
CMV model (POLIC et al., 1998). Furthermore, adoptively transferred 
CD8 T cells only remained detectable in transplant recipients if CD4 T cells were 
present (WALTER et al., 1995). In addition, recovery of renal transplant 
recipients from HCMV disease was only achievable in the presence of functional 
CD4 T cells (GAMADIA et al., 2003).  
In murine animal models, NK cells were shown to be necessary to control CMV 
infection (TAY et al., 1999). This goes in parallel with the observation of a more 
severe HCMV disease in a patient with NK cell deficiency (BIRON et al., 1989).  
These considerations are not unexpected as various different components of the 
innate immune system and the adaptive one interact with each other to 
successfully control pathogenic agents; nevertheless, developing immunization 
should address CD4 and CD8 T cell responses that control HCMV diseases. 
3.4. HCMV antigen presentation with MVA as vector vaccine 
A correct presentation of HCMV antigens by recombinant MVA-infected host 
T cells to the immune system requires processing of HCMV antigens in the 
cytoplasm before loading them onto MHC molecules. The recognition of 
HCMV-infected cells by epitope-specific cytotoxic T cells is dependent on the 
allelic variants of epitope-presenting MHC molecules. Thereby, different 
HLA-A, -B, and -C molecules present different range of epitopes of HCMV to their 
corresponding cytotoxic T cells.  
For a long time it has been known that recombinant MVAs are able to induce 
protection against infections by both cellular and humoral immune responses 
(SUTTER et al., 1994). During MVA infection, cross-presentation by APCs is 
most important for the activation of cytotoxic T cells (GASTEIGER et al., 2007; 
PASCUTTI et al., 2011). To enable correct cross-presentation, a long-lasting 
antigen is proposed to be the best precondition (GASTEIGER et al., 2007). A 
recent study showed that foreign antigens of recombinant MVA are addressing 
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CD4 T cells by displaying peptides via the endogenous MHC class II pathway 
(THIELE et al., 2015).  
Taken this together, MVA is a promising vector vaccine platform as it ensures a 
very efficient presentation of foreign antigens and is able to activate both major 
subsets of the adaptive cellular pathway, CD4 T cell and CD8 ones.  
4. Objectives 
Since several decades many different research groups focused their efforts on 
the generation of a vaccine to prevent HCMV disease. However, there is not 
even a single licensed vaccine against HCMV available, yet.  
For this purpose, an HCMV vaccine candidate (MVA-pp65/IE-1) based on the 
very safe and efficient MVA backbone with several novel features had recently 
been constructed in our laboratory.  
This study describes the genetical analysis of MVA-pp65/IE-1 in comparison to 
MVA-pp65 and MVA-IE-1. Moreover, the data confirms that HCMV-MVA-infected 
CD40 B cells are a valuable tool for studying the functional properties of 
HCMV-encoding MVAs.  
Lastly, this study includes the immunological characterization of MVA-pp65/IE-1 
in relation to MVA-pp65 and MVA-IE-1 by evaluation of the expansion and 
functionality of HCMV-specific T cells using CD40 B cells.  
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III.  MATERIAL AND METHODS 
1. Oligonucleotide primers  
Table 1 lists the binding sites of oligonucleotide primers for Human herpesvirus 4 
complete wild-type genome (EBV, GenBank: NC_007605.1), Homo sapiens 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GenBank: 
NM_001256799.2), and complete genome of vaccinia virus strain Acambis 3000 
Modified Virus Ankara (MVA) (GenBank: AY603355).  
 
Oligonucleotide 
primers
Nucleotide sequence 
Oligonucleotide 
binding site 
PCR product 
size
gp85c
5’-TGG TCA GCA GCA GAT 
AGT GAA CG-3’ 128,761-128,783
gp85d
5‘-TGT GGA TGG GTT TCT 
TGG GC-3‘ 129,202-129,221
GAPDH-F3
5‘-GAC ATC AAG AAG 
GTG GTG AAG CAG-3‘ 991-1,014
GAPDH-B4
5‘-AAG TGG TCG TTG AGG 
GCA ATG-3‘ 1,122-1,142
MVA-Del 1-F 
5‘-CTT TCG CAG CAT AAG 
TAG TAT GTC-3‘ 3,896-3,919
MVA-Del 1-R
5’-CAT TAC CGC TTC ATT 
CTT ATA TTC-3’ 4,163-4,186
MVA-Del 2-F
5’-GGG TAA AAT TGT AGC 
ATC ATA TAC C-3’ 14,795-14,819
MVA-Del 2-R
5‘-AAA GCT TTC TCT CTA 
GCA AAG ATG-3‘ 15,125-15,148
MVA-Del 3-F
5‘-GAT GAG TGT AGA TGC 
TGT TAT TTT G-3‘ 143,359-143,383
MVA-Del 3-R
5‘-GCA GCT AAA AGA ATA 
ATG GAA TTG-3‘ 143,781-143,804
MVA-Del 4-F
5‘-AGA TAG TGG AAG ATA 
CAA CTG TTA CG-3‘ 160,856-160,881
MVA-Del 4-R
5’-TCT CTA TCG GTG AGA 
TAC AAA TAC C-3’ 161,333-161,357
MVA-Del 5-F
5‘-CGT GTA TAA CAT CTT 
TGA TAG AAT CAG-3‘ 13,685-13,711
MVA-Del 5-R
5‘-AAC ATA GCG GTG TAC 
TAA TTG ATT T-3‘ 14,263-14,287
MVA-Del 6-F
5’-CGT CAT CGA TAA CTG 
TAG TCT TG-3’ 116,788-116,810
MVA-Del 6-R
5‘-TAC CCT TCG AAT AAA 
TAA AGA CG-3‘ 117,467-117,489
603 bp
702 bp
461 bp
152 bp
291 bp
354 bp
446 bp
502 bp
Tab. 1: Oligonucleotide primers.
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2. Antibodies 
Specificity Conjugate Clone Company
CD19 FITC HIB19 BioLegend, San Diego, USA
CD8a APC RPA-T8 BioLegend, San Diego, USA
KIR2DL2/3 FITC CH-L
BD Biosciences, Heidelberg, 
Germany 
Dilution Company
1: 500
Ray Biotech, Inc., Norcross, 
USA
1: 200
Santa Cruz Biotechnology, Inc., 
Texas, USA
1: 10,000 Millipore, Darmstadt, Germany
1: 200
Hybridoma culture supernatants 
(BACKES et al., 2010)
1: 200 Mobitec, Berkheim, Germany
1: 20,000 BioLegend, San Diego, USA
Dilution Company
1: 2,000
Acris GmbH, Arnbruck, 
Germany
1: 5,000
Jackson Immuno Research, 
West Grove, USA
mouse-anti-CMV pp65 
Antibodies used for flow cytometry
Antibodies used for Western blot 
Specificity
mouse anti-CMV pp72 IEA 
Specificity
rabbit anti-VACV 
goat anti-rabbit 
mouse anti-GAPDH 
rat anti-VALV C7 
anti-mouse MFP488 (A1001)
anti-rat HRP 
Antibodies used for Immunostaining 
Tab. 2: Antibodies.
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3. Peptides 
The HCMV-specific peptides (JPT, Berlin, Germany) used in this study are listed 
in Table 3, had >70% purity, and were dissolved in 100% dimethyl sulfoxide 
(DMSO).  
Antigen
Amino acids 
sequence 
(short name)
HLA 
restriction
Amino acids 
position 
References
VLEETSVML 
(VLE)
HLA-A*02:01 316-324 
(KHAN et al., 
2002)
ILEETSVML 
(ILE)
HLA-A*02:01 316-324
CRVLCCYVL 
(CRV)
HLA-C*07:02 309-317
(AMERES et al., 
2013)
ELKRKMMYM 
(ELK) 
HLA-B*08:01 199-207
(ELKINGTON et 
al., 2003)
TMYGGISLL 
(TMY)
HLA-A*02:01 297-304
(GALLEZ-
HAWKINS et al., 
KEVNSQLSL 
(KEV)
HLA-B*40:01 42-50
(KHAN et al., 
2007)
RIKEHMLK 
(RIK)
HLA-A*03:01 99-107
(AMERES et al., 
2013)
NLVPMVATV 
(NLV)
HLA-A*02:01 495-503
(DIAMOND et 
al., 1997)
TPRVTGGGAM 
(TPR)
HLA-B*07:02 417-426
(WILLS et al., 
1996)
RPHERNGFTVL 
(RPH)
HLA-B*07:02 265-275
(LONGMATE et 
al., 2001)
IPSINVHHY 
(IPS)
HLA-B*35:01 123-131
(GAVIN et al., 
1993)
HCMV pp65
HCMV IE-1
Tab. 3: Peptides.
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4. Peptide/human leucocyte antigen (HLA) multimers 
Antigen Peptide
HLA 
restriction
Type of multimer
Used in 
donor
HCMV pp65 NLV A*02:01 dextramer-PE A
HCMV pp65 NLV A*02:01 pentamer unlabeled C-E
HCMV IE-1 VLE A*02:01 pentamer unlabeled A, C-E
HCMV IE-1 ELK B*08:01 pentamer unlabeled A
HCMV pp65 IPS B*35:01 pentamer unlabeled E
HCMV IE-1 CRV C*07:02 streptamer B
HCMV pp65 TPR B*07:02 pentamer unlabeled B
HCMV pp65 RPH B*07:02 pentamer unlabeled B
Tab. 4: Peptide/HLA multimers.
 
Companies:  
Pentamers (n=5) unlabled and Pro5 Fluorotag R-PE (PROIMMUNE, Oxford, 
England); Dextramer-PE (>5) (Immudex, Kopenhagen, Denmark); Streptamer 
(n=4) (Fabian Schlott/ Dirk Busch/ Michael Neuenhahn, Institute for Medical 
Microbiology, Immunology and Hygiene, TU München). 
5. Cells 
5.1. Cell culture 
Peripheral blood mononuclear cells (PBMC) were isolated from human buffy 
coats (Institute of Transfusion Medicine, University of Ulm, Germany). 
CD40-stimulated B cells and polyclonal T cell lines were generated from PBMC 
in this study (Sections III.5.5 and III.5.6). Murine fibroblasts expressing human 
CD40 ligand (LL8) were used to keep CD40 B cells in culture. LL8 cells, PBMC, 
polyclonal T cells, and CD40-stimulated B cells were maintained in RPMI-1640 
medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin/ 
100 µg/ml streptomycin (P/S), and 100 nM sodium selenite (Se) ( standard 
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medium ). 
Chicken embryo fibroblasts (CEF) were freshly prepared from pathogen-free 
chicken eggs (Charles River SPAFAS or VALO Biomedia) and incubated for 
11 days. CEF and baby hamster kidney cells (BHK) were maintained in Minimum 
Essential Medium Eagle (MEM) supplemented with 10% FCS, P/S, and 
1% non-essential amino acids (NEAS). 
Human keratinocyte cell line (HaCaT) was maintained in VLE Dulbecco’s MEM 
(DMEM) supplemented with 10% FCS, P/S, and 2% 1 M HEPES. 
Cells were cultivated in a humidified incubator at 37°C under 5% CO2. During 
infection, all cells were kept in medium with 2% FCS. Dense cell culture flasks 
were split 1-2 times per week. Trypsin-EDTA was added to detach the cells.  
5.2. Cell counting 
Cells were diluted (1:1 or 1:10) with Trypan blue solution containing of 
0.1% trypan blue and 0.2% sodium azide in sodium phosphate buffer for 
live/death staining before counting with a Neubauer Chamber. 
5.3. Cryopreservation of cells 
PBMC (donor A-E), polyclonal T cells (donor A+B), and CD40-stimulated B cells 
(donor A+B) were resuspended in cold RPMI-1640/FCS/DMSO mixed at a ratio 
of 5:4:1. The polyclonal T cells (donor C-E) and CD40-stimulated B cells (donor 
C-E) were resuspended in cold FCS/DMSO at a ratio of 9:1 immediately before 
transfer to -80°C. Long-term storage was in the gas phase over liquid nitrogen. 
5.4. Isolation of peripheral blood mononuclear cells 
PBMC were purified from buffy coats of five CMV positive healthy HLA class I 
typed donors (donor A, A1/A2 B8/B60; donor B, A3/A28 B7/B63; donor C, A2/A2 
B44/B60; donor D, A2/A3 B47/B60; donor E, A2/A11 B35/B44) by density 
gradient centrifugation using Ficoll/Hypaque (Biochrom). The total volume of 
each buffy coat was divided equally into 2 50 ml falcon tubes, filled up to 40 ml 
with phosphate buffered saline (PBS) and mixed. The buffy coat/PBS mixture 
was gently underlaid with 10-12 ml Ficoll and centrifuged at 1,200   g for 25 min 
at room temperature. Afterwards, the PBMC layer was carefully harvested, 
washed 4-5 times by adding 50 ml PBS and centrifuged at 350-400   g. Finally, 
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PBMC were counted and partly used for generation of permanent 
CD40-stimulated B cells. The remaining PBMC were cryopreserved for later use. 
5.4.1. HCMV IgG serostatus in blood donors 
HCMV serostatus was determined from diluted plasma by HCMV-ELISA kit 
(EnzygnostR Anti-CMV/IgG, Siemens) following the supplier’s instructions. 
5.5. Generation of CD40-stimulated B cells 
CD40-stimulated B cells were generated from PBMC according to Wiesner et al, 
2008. 
Firstly, LL8 cells were irradiated with 180 Gy and plated either in 24-well or 
96-well flat bottom plates. After 1 day, PBMC were added on LL8 cells in different 
concentrations (2.5, 5, 10, 20   104 cells per well of a 96-well plate or 12.5, 25, 
50, 100   104 cells per well of a 24-well plate). Standard cell culture medium was 
supplemented with IL-4 (2 ng/ml). Reactivation of T cells and NK cells was 
prevented by adding 1 µg/ml cyclosporine A throughout the first four weeks of 
cultivation. B cells were seeded on newly irradiated LL8 cells once per week until 
stably proliferating CD40 B cells were obtained on 12-well plates for each donor. 
The lowest initial concentration of PBMC leading to stable CD40 B cell cultures 
were chosen for further cultivation. Cells were cultured in 12-well plates, split 
1-2 times per week, and seeded on recently irradiated LL8 cells until they were 
used for later experiments. 
5.6. Generation of HCMV-specific polyclonal T cell lines 
Polyclonal peptide-stimulated T cell cultures were generated from cryopreserved 
PBMC of HCMV seropositive donors. For this purpose, about 15   106 PBMC 
were cultured together with one of the following HCMV-specific peptides 
(5 µg/ml): NLVPMVATV, pp65 aa 495-503, HLA-A*02:01-restricted (abbreviated 
NLV) (DIAMOND et al., 1997); VLEETSVML, IE-1 aa 316-324, 
HLA-A*02:01-restricted (abbreviated VLE) (KHAN et al., 2002); ILEETSVML, IE-1 
aa 316-324, HLA-A*02:01-restricted (abbreviated ILE), CRVLCCYVL, IE-1 aa 
309-317, HLA-B*07:02-restricted (abbreviated CRV) (AMERES et al., 2013), and 
RPHERNGFTVL, pp65 aa 265-275, HLA-B*07:02-restricted (abbreviated RPH) 
(LONGMATE et al., 2001), in a final volume of 5 ml for 1 h at 37°C.  
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Afterwards, cells were washed 3 times with PBS and centrifuged at 350   g for 
10 min each. Thereafter, PBMC were resuspended to a final concentration of 
2.5   106 cells/ml in standard medium supplemented with IL-2 (25 U/ml). Then, 
cells were incubated for 10 days at 37°C. At days 4 and 7, 50% of the cellular 
supernatant was replaced by fresh medium supplemented with IL-2 (25 U/ml). 
After 10 days all cells were harvested, counted, and stored in aliquots in gas 
phase over liquid nitrogen until they were used in further experiments. 
6. Viruses 
6.1. Viruses used in this study 
All HCMV-MVAs had been generated by homologous recombination before the 
start of this study.  
Intron 1HCMV IE-1 gene:
HCMV IE-1 cDNA:
5‘ - - 3‘
In silico deletion of NLS
In silico deletion of
STAT2 binding site
HCMV  IE-1  N/S2  cDNA:
HCMV  pp65 cDNA: 5‘ - - 3‘CMV  pp65
In silico fusion of HCMV pp65 
with HCMV IE-1  N/S2:
ATG
5‘ - - 3‘ATG
5‘ - - 3‘ATG
5‘ - CMV  pp65 - 3‘ATG
Intron 2 Intron 3
Fig. 3: In silico construction of the HCMV pp65/IE-1 gene. Gene sequences of pp65
and IE-1 originate from HCMV strain TB40E. Modified IE-1 (IE-1N/S2) lacks the nuclear
localization signal (NLS) and the STAT2 binding site. A fusion gene of IE-1N/S2 and pp65
was synthesized de novo for cloning into MVA (personal information by M. H. Lehmann).
 1-25
 1-25  421-475
 421-475


 
MVA-pp65/IE-1 was generated based on MVA (clonal isolate F6) as described in 
(MEYER et al., 1991). The full length pp65 gene (HCMV strain TB40E) and a 
truncated version of the IE-1 gene (HCMV strain TB40E) lacking the nuclear 
localization signal (NLS; aa, 1-25) and the STAT2 binding site (aa, 421-475), 
were constructed in silico as a fusion gene (Fig. 3), gene synthesized, cloned into 
plasmid pIIIH5redK1L, included into deletion site III of the MVA genome by 
homologous recombination and encoded under transcriptional control of the 
Modified Vaccinia virus promoter PmH5 (WYATT et al., 1996). Marker gene 
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deletion occurred during plaque passaging. Those virus plaques, missing the 
marker gene, were selectively picked and separately amplified (Fig. 4). MVA 
clonal isolate F6 (MEYER et al., 1991) was used as non-recombinant control 
virus. The MVA-IE-1 and MVA-pp65 viruses were generated based on 
MVA-II new (STAIB et al., 2003). Either the full length pp65 gene or the full length 
IE-1 gene of the HCMV strain AD169 was inserted into deletion site III of the 
MVA genome by homologous recombination and put under the control of the 
PmH5 and the VACV E3L promoter, respectively. 
 
 
6.2. Virus handling 
Viruses were long term stored at -80°C. Before using viruses in assays, they 
were thawed on ice and always sonicated 3 times for 1 min each. 
6.3. Amplification/Purification 
Amplification of viruses was performed on CEF cell monolayers. Cells were 
infected with virus and incubated for 3 to 5 days at 37°C. Flasks were frozen 
when widespread cytopathic effects were observed. 
  
III. Material and Methods     29 
Cells were subjected to 3 freeze-thaw cycles and centrifuged at 36,057   g for 
3 h at 4°C (Avanti J-26XP, Beckman Coulter). Pellets were carefully 
resuspended in a total volume of 20 ml virus buffer (10 mM Tris-HCl; pH 9.0). 
Thereafter, this suspension was sonicated 3 times for 15 sec and centrifuged at 
290   g for 5 min at 4°C. Then, the supernatants were collected and pellets were 
resuspended in 5 ml virus buffer (10 mM Tris-HCl; pH 9.0). These steps were 
repeated 3 times. 
Next, the supernatant was purified by 36% sucrose gradient centrifugation. For 
this purpose, autoclaved plastic tubes were filled with 15 ml sucrose and 40 ml 
supernatant was carefully added to the buffer before centrifugation (OptimaTM 
LE-80K Ultracentrifuge, Beckman Coulter) at 40,500   g for 90 min at 4°C. 
Finally, the pellets were resuspended in virus buffer (10 mM Tris-HCl, pH 9.0) in 
a total volume of 1.5 to 3 ml depending on pellet size and stored in -80°C. 
6.4. Titration/Immunostaining 
Virus titration was performed on confluent CEF monolayers in 6-well plates. 
Tenfold serial virus dilutions (10-1-10-9) were added in duplicates to CEF cells and 
incubated for 2 h at 37°C. After washing with 2 ml MEM/P/S/NEAS, 
MEM/2%FCS/P/S/NEAS was added. Then, plates were incubated for 48 h at 
37°C. Fixation and permeabilization of cells was performed with ice-cold 
acetone-methanol (1:2) at room temperature for 5 min. Unspecific binding was 
blocked by PBS/3%FCS overnight at 4°C. 
Rabbit anti-VACV (Acris GmbH) was added at the dilution 1:2,000 in 
PBS/3%FCS for 1 h at room temperature. Plates were shaken during incubation 
to ensure antibody distribution. Plates were washed 2 times with PBS. Secondary 
goat anti-rabbit (Jackson Immuno Research) was added at the dilution 1:5,000 
for 1 h in PBS/3%FCS. Cells were washed 2 times with PBS and stained with 
0.5 ml True BlueTM Peroxidase (KPL) per well. Finally, plaques were counted 
after approximately 20 min. 
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6.5. Multi-step growth kinetic assays of recombinant HCMV-MVAs  
CEF and HaCaT monolayers were infected with MVA, MVA-IE-1, MVA-pp65, and 
MVA-pp65/IE-1 at a multiplicity of infection (MOI) of 0.01. After 30 min of 
incubation at 4°C cells were washed with MEM/P/S/NEAS medium and thereafter 
2 ml MEM/2%FCS/P/S/NEAS or DMEM/2%FCS/P/S/HEPES were added, 
respectively. Cells were incubated at 37°C and frozen at different points in time 
post infection (0, 4, 12, 24, 48, or 72 h). Cells and supernatants were subjected 
to 3 freeze-thaw cycles, resuspended and 750 µl per well was harvested for virus 
plaque assay. Virus-titration was performed on 6-well CEF monolayers. Samples 
from HaCaT and CEF cell monolayers were diluted at 10-6 and 10-8, respectively. 
Virus titration was performed as described in Section III.6.4. 
7. Polymerase chain reaction (PCR) 
7.1. MVA 6-deletion PCR 
BHK were infected with MVA at an MOI of 5 and incubated for 24 h. Cells and 
supernatants were harvested, centrifugated at 290   g for 5 min, and 
resuspended in a remaining volume of 250 µl. Genomic viral DNA was purified 
using QIAamp DNA Mini Kit (Qiagen) following the company’s protocol. In order 
to yield a higher concentration of DNA, the samples were digested for 3 h with 
proteinase K in the first step of purification.  
Polymerase chain reaction (PCR) was performed using 50 ng DNA (1 µl) and 
PCR-mixture of 24 µl composed of: 
19.8 µl distilled water 
  2.5 µl buffer (10 ) 
  0.5 µl forward oligonucleotide primer 
  0.5 µl reverse oligonucleotide primer  
  0.5 µl dNTP’s 
  0.2 µl Dynazyme II 
 
MVA-Del1-6 oligonucleotide primers were used, as listed in Tab. 1. The following 
PCR-protocol was applied for 6-deletion PCR using peqSTAR 2  thermocycler 
(PEQLAB Biotechnology GmbH). Initial denaturation was performed for 3 min at 
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95°C followed by 30 cycles of denaturation for 30 sec at 95°C, 
primer-hybridization for 45 sec at 57°C, and elongation for 1 min and 15 sec at 
72°C. Final elongation step was conducted for 5 min at 72°C. 
7.2. CD40 B cells dual PCR 
CD40-stimulated B cells were pelleted, supernatants were removed and cells 
were resuspended in 200 µl PBS. Samples were treated with proteinase K for 3 h 
and DNA was extracted using QIAmp DNA Mini Kit (Qiagen) by following the 
manufacturer’s protocol. PCR was performed using gp85c and gp85d as 
oligonucleotide primers suitable for amplification of BXLF2 gene. Additionally, 
GAPDH-F3 and GAPDH-B4 oligonucleotide primers were added to amplify 
cellular GAPDH. B95.8-infected B lymphoblastoid cell line (kindly provided by 
Xiaoling Liang, Helmholtz Zentrum München) served as positive control. Dual 
PCR using peqSTAR 2  thermocycler (PEQLAB Biotechnology GmbH) was 
performed with initial denaturation for 3 min at 96°C, 30 cycles of denaturation at 
96°C, primer-hybridization at 59°C, and elongation at 72°C were conducted for 
45 sec each. Final elongation lasted for 5 min at 72°C.  
8. Gel electrophoresis 
PCR products were size-separated by agarose gel electrophoresis. Gel RedTM 
was used to visualize nucleic acids. DNA was mixed with loading buffer before it 
was loaded onto the gel. The composition of buffers is described in Appendix 
IX.1. Ready to use DNA standard (F-303SD, Thermo Fisher Scientific) was 
applied as molecular weight marker. Furthermore, gel ran in 1   TAE buffer and 
nucleic acid was detected using ChemiDocTMMP, Imaging System (Bio-Rad). 
9. Western blot analysis 
9.1. Verification of HCMV gene expression in recombinant MVAs 
BHK monolayers were infected with MVA, MVA-IE-1, MVA-pp65, or 
MVA-pp65/IE-1 at an MOI of 5. After 24 h, supernatants were removed and cells 
were harvested with lysis buffer and kept on ice. Samples were loaded onto 4-
20% Criterion TGX stain free gel (Bio-Rad) and protein electrophoresis (Power 
Ease 500, Invitrogen life technologies) was performed in Tris-Glycine buffer (1 , 
Bio-Rad) for 90 min at 100 V. Precision Dual Color protein ladder (Bio-Rad, 
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Fig. 7: red) was used as molecular weight marker. Proteins were transferred onto 
a 0.2 µm nitrocellulose membrane (Bio-Rad) using Bio-Rad Trans Blot Turbo 
system. Blot was blocked in Tris-buffered saline and 0.1% Tween20 (TBS/T) 
supplemented with 5% BSA overnight. Membrane was washed 3 times in TBS/T 
for 10 min per wash. 
Mouse anti-CMV pp72 IEA (1:500, Ray Biotech, Inc.), mouse-anti-CMV pp65 
(1:200, Santa Cruz), and mouse anti-GAPDH (1:10,000, Millipore) were added at 
the indicated dilutions in TBS/T/5% BSA for 1 h. Membrane was washed 3 times 
in TBS/T for 10 min per wash. Secondary anti-mouse MFP488 (1:200, Mobitec 
A1001, Fig. 7: blue) was added in TBS/T/5% BSA for 1 h and membrane was 
washed 3 times for 10 min each time in TBS/T. Rat polyclonal anti-C7L (1:200) 
(BACKES et al., 2010) was added in TBS/T/2.5% milk for 1 h. Membrane was 
washed 3 times in TBS/T for 10 min per wash. Secondary anti-rat HRP 
(BioLegend, Fig. 7: green) was added at a dilution 1:20,000 for 1 h in 
TBS/T/2.5% milk. Positive signals were visualized using Clarity™ ECL Western 
Blotting Substrate using a ChemiDocTMMP Imaging System (Bio-Rad) and 
analyzed with Image Lab 5.0 software (Bio-Rad).  
9.2. Verification of HCMV gene expression in fifth passage of 
MVA-pp65/IE-1 
BHK monolayer was infected with MVA-pp65/IE-1 at an MOI of 0.01. After 60 h, 
cells and supernatant were harvested and virus titer was determined as 
described in Section 6.4. First passage was diluted 1:1,000 before infecting the 
next BHK monolayer to obtain roughly the same MOI of 0.01. Passages 2 to 5 
were performed similarly.  
The titer of the fifth passage of MVA-pp65/IE-1 was verified (Section III.6.4). To 
obtain single plaques the fifth passage of MVA-pp65/IE-1 was seeded in 10-fold 
serial dilutions on BHK monolayers in 96-well plates. After 48 h, 30 single 
plaques were picked and amplified on BHK monolayers for 4 days before 
Western blot was performed.  
Supernatants were removed, cells were resuspended in lysis buffer and kept on 
ice until usage. Samples were loaded onto a 10% SDS-page gel and protein 
electrophoresis (Power Ease 500, Invitrogen life technologies) was performed in 
III. Material and Methods     33 
Tris-Glycine buffer for 90 min at 100 V. Precision Dual Color protein ladder 
(Bio-Rad) was used as molecular weight marker. Proteins were transferred onto 
a 0.2 µm nitrocellulose membrane (GE Healthcare) using Bio-Rad Trans Blot 
Turbo system. The membrane was incubated in Tris-buffered saline and 
0.1% Tween20 (TBS/T) supplemented with 5% BSA overnight to block unspecific 
binding of antibodies. Membrane was washed 3 times in TBS/T for 10 min per 
wash. 
Mouse anti-CMV pp72 IEA (1:500, Ray Biotech, Inc.) and mouse anti-GAPDH 
(1:10,000, Millipore) were added in TBS/T/5% BSA for 1 h. The membrane was 
washed 3 times in TBS/T for 10 min each. Secondary anti-mouse MFP488 
(Mobitec A1001) was added (1:200) in TBS/T/5% BSA for 1 h. Afterwards, 
membrane was washed 3 times in TBS/T for 10 min. Positive signals were 
visualized using a ChemiDocTMMP Imaging System (Bio-Rad) and analyzed with 
Image Lab 5.0 software (Bio-Rad). 
10. Immunological assays 
10.1. Propagation of HCMV-specific CD8 T cells by stimulation with 
MVA-infected cells 
CD40 B cells from established cultures were harvested, centrifuged at 350   g 
for 10 min and resuspended in standard medium. Then, cells were irradiated 
(54 Gy), infected with MVA, MVA-IE-1, MVA-pp65, or MVA-pp65/IE-1 at an MOI 
of 0.2 and incubated for 2 h at 37°C. PBMC and MVA-infected CD40 B cells were 
cultured together in 2 ml at a rate of 5:1. The total number of PBMC varied 
between 8-40   106 cells. At day 4 and day 7, 50% fresh medium 
(RPMI-1640/10%FCS/P/S/Se) supplemented with IL-4 (25 U/ml) was added to 
the cells. After 10 days, cells were harvested, counted, and stored in aliquots in 
gas phase over liquid nitrogen until used in further analyses. 
10.2. Activation of IFN- -producing HCMV-specific polyclonal T cells after 
incubation with MVA-infected CD40 B cells 
Autologous CD40 B cells were infected with MVA, MVA-IE-1, MVA-pp65, or 
MVA-pp65/IE-1 at an MOI of 0.5 and incubated for 2 h at 37°C. CD40 B cells 
cultured together with one of the following HCMV-specific peptides (5 µg/ml), 
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NLV; VLE; ILE; CRV; or RPH for 1 h served as positive controls. After peptide 
loading, B cells were washed once with 50 ml PBS. The polyclonal T cells were 
thawed, resuspended in pre-warmed standard medium, and counted. 
2.5   104 CD40 B cells and 5   104 polyclonal T cells per well of a V-bottom 
96-well plate were co-cultured in triplicates for 16-18 h at 37°C. Plates were 
centrifuged at 350   g for 10 min and 50 µl supernatant per well was used for 
IFN-  detection. IFN-  secretion was measured with human-IFN-  ELISA kit 
(MABTECH) following the manufacturer’s instructions.  
Measurement of optical density at 405 nm was conducted in an ELISA reader 
(Universal Microplate Reader EL-800, BIO-TEK Instruments) and analyzed using 
KC4 software (TreeStar Inc.). 
11. Fluorescence activated cell sorting (FACS) 
11.1. Preparation of samples for flow cytometry analysis 
PBMCd0 (6   105 cells/peptide) and PBMCd10 (3   105 cells/peptide), after 
10 days propagation of HCMV-specific T cells, were stained in a 2 or 3 step 
process, depending on the HLA/peptide multimer that was applied. 
Cells were washed with 900-950 µl PBS/2%FCS between each incubation step 
and centrifuged for 3 min at 1,000   g. Cells were stained with different 
HLA/peptide multimers (Tab. 4) in 25 µl PBS/2%FCS for 15 min at room 
temperature. Afterwards, cells were stained with APC-conjugated anti-CD8 
antibody, FITC-conjugated anti-CD19 antibody (donor A, donor C-E), and 
additionally with PE-conjugated Fluorotag (Proimmune), if HLA/peptide multimers 
(Proimmune) had been applied in the first step. Donor B was stained with 
FITC-conjugated anti-CD158b (KIR2DL2/3) instead of FITC-conjugated 
anti-CD19 antibody (Fig. 14).  
Cells were analyzed on a FACS Calibur (BD Biosciences). Cells were gated 
based on forward/side scatter and an additional lymphocyte gate was included. 
0.5-1   105 lymphocyte-gated events were counted per sample. Data was 
analyzed with CellQuestTM Pro Software (BD Biosciences). 
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11.2. Calculation of HCMV-specific T cell propagation and specific expansion 
Propagation   and specific expansion   of HCMV-specific T cells within the 
PBMC population were calculated out of the analyzed flow cytometer data using 
the following formulae: 
 
Propagation  : 
                              
   = proportion of multimer positive cells within CD8 T cells   = proportion of CD8 T cells within the total number of PBMC   = proportion of multimer positive cells within CD8 T cells in negative control 
(staining without MHC class I/peptide complex)   = proportion of CD8 T cells within the total number of PBMC in negative control 
(staining without MHC class I/peptide complex)     = PBMC at day 10 after propagation of HCMV-specific T cells     = PBMC at day 0 
 
Specific expansion (E): 
                     
        = total number of PBMC after   days, where        . 
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12. Propagation of IFN-  producing HCMV IE-1-specific T cells  
12.1. Cell suspension analyzed with ELISPOT assay 
ELISPOT plates (Multi Screen HTS Filter plates, Millipore) were pre-coated with 
anti-IFN-  antibody (mAb 1-D1K) at a dilution of 15 µg/ml (50 µl per well) and 
incubated overnight at 4°C. Then, plates were washed 5 times with 
PBS/0.05% Tween20 and blocked with 200 µl standard medium per well for at 
least 30 min at room temperature. PBMCd0 (1   105 cells/well) were incubated in 
coated ELISPOT wells with HCMV-specific peptides: VLE; ILE; KEVNSQLSL, 
IE-1 aa 42-50, HLA-B*40:01-restricted (abbreviated KEV); RIK aa 99-107, 
HLA-A*03:01-restricted (abbreviated RIK); and TMYGGISL, IE-1 aa 297-304, 
HLA-A*02:01-restricted (abbreviated TMY) in triplicates for 16-18 h. PBMCd10 
were thawed and counted. PBMCd10 (2.5   104/well) were incubated in triplicates 
together with CD40 B cells (5   104/well) and HCMV-specific peptides (5 µg/ml) 
on ELISPOT plates for 16-18 h. IFN-  spots were developed using the human 
IFN-  ELISPOT Kit from Mabtech (Nacka Strand, Sweden) following the 
company’s instructions. IFN-  spots were counted with ImmunoSpot 5.0 Analyzer 
ProCD (ImmunoSpot, Cellular Technology Ltd. C.T.L.). 
12.2. Supernatants analyzed with ELISA 
PBMCd10 were thawed and counted. 2.5   104 PBMCd10/well were incubated 
together with autologous CD40 B cells (5   104/well) and different HCMV IE-1 
peptides (5 µg/ml): VLE; ILE; KEV (KHAN et al., 2007); RIK (AMERES et al., 
2013); and TMY (GALLEZ-HAWKINS et al., 2003) in triplicates for 16-18 h. 
Supernatants were analyzed with human IFN-  ELISA Kit from Mabtech. 96-well 
flat bottom plates (Nunc Maxisorp) were pre-coated with anti-IFN-  antibody 
(mAb 1-D1K) in a dilution of 2 µg/ml which stayed on the plates overnight at 4°C. 
Then, plates were washed 5 times each with PBS/0.05%Tween20 and blocked 
with 200 µl standard medium (RPMI-1640/10%FCS/P/S/Se) per well for 1 h at 
room temperature. Cytokine standard was prepared (triplicates of dilutions: 
20,000; 4,000; 800; 160; 32 pg/ml). Supernatants and cytokine standards 
(50 µl/well) were added to the antibody-coated 96-well flat bottom plates and 
incubated for 2 h at room temperature. After washing 5 times, secondary 
antibody (7-B6-1-Biotin) was added and incubated for 1 h, followed by 5 times 
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washing. Streptavidin-alkaline phosphatase (ALP) was added for 1 h and plates 
were washed 5 times. ALP substrate solution containing 10% diethanolamine, 
1 mg/ml para-nitrophenyl-phosphate (p-NPP), and 0.8 mM MgS04 was added 
and incubated for 10 min to 2 h as needed. Absorption was measured with a 
Universal Micro plate Reader (EL800, Bio Tec. Instruments) at 405 nm and 
analyzed using KC4 software (TreeStar Inc.). 
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IV.  RESULTS 
1. Genetic characterization of recombinant HCMV-MVAs 
This study focuses on the characterization of our most promising MVA-pp65/IE-1 
vaccine candidate. To begin with, a series of experiments was conducted in order 
to genetically analyze MVA-pp65/IE-1 as well as the other recombinant MVAs 
that served as comparisons in the following studies. 
1.1. Verification of correct insertion of HCMV genes and of MVA backbone 
integrity 
Our lab had established MVA-specific oligonucleotide primer sets (MVA-Del I-VI) 
that are frequently used in PCR analyses to ensure proper insertion of foreign 
genes into our recombinant MVA viruses as well as their genetic purity and MVA 
integrity. Those MVA-Del I-VI oligonucleotide primers had been designed in a 
way that they flank the six major deletion sites of the non-recombinant MVA 
genome and amplify one distinct PCR fragment of specific size, each (Fig. 5, 
Expected sizes without insert panel B ) (KREMER et al., 2012). 
All recombinant HCMV-MVAs used in this study had been generated by 
homologous recombination of nucleotide sequences encoding HCMV genes into 
the existing deletion site III (Del III) of the MVA backbone. Thus, specific 
MVA-Del III oligonucleotide primers were applied to amplify PCR fragments of 
predetermined molecular weights (Fig 5a, Expected sizes panel A ) from DNA of 
MVA by PCR. 
The expected molecular weights of the PCR fragments had been calculated by 
adding the respective nucleotide sequences’ length of IE-1, pp65, and pp65/IE-1 
to the sizes of the corresponding PCR fragments shown in Fig. 5a, Expected 
sizes without insert panel B .  
Presence of predicted PCR fragments was detectable in all samples except the 
negative control, in which DNA was replaced by water. Furthermore, the specific 
non-recombinant MVA PCR band (446 bp) was only detectable in the control 
sample, which contained DNA from a non-recombinant MVA, and was absent 
from all tested recombinant HCMV-MVAs (Fig. 5a). These observations 
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confirmed the correct insertion of HCMV genes into Del III and genetic purity of 
all recombinant HCMV-MVAs.  
Fig. 5: PCR assay to check for proper insertion of HCMV genes and MVA identity.
PCR from viral DNA was performed using specific oligonucleotide primers for deletion I-VI
(Del I - Del VI). (A) HCMV-gene insertion proven by deletion III PCR from viral DNA of MVA,
MVA-IE-1, MVA-pp65, and MVA-pp65/IE-1. (B) PCR of MVA-pp65/IE-1 (left panel) and
wild-type MVA (right panel) using MVA-Del 1 - MVA-Del 6 oligonucleotide primers. Molecular
weight marker (MWM); Control PCR without DNA (C). Del I-VI (I-VI).
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 Moreover, MVA-pp65/IE-1 candidate vaccine was tested for genetic integrity of 
the MVA backbone. By adding the corresponding oligonucleotide primer set, six 
PCRs (Del I-VI) of viral DNA were performed for either MVA-pp65/IE-1- or 
MVA-infected cells, each. PCR fragments of both viruses were visualized and 
compared to identify differences in their molecular weight sizes. As expected, all 
PCR products showed similar results for all PCRs except from Del III PCR 
(Fig. 5b). 
Finally, the genetic stability of MVA-pp65/IE-1 was checked by passaging the 
virus five times in BHK. Viral DNA was isolated and all six PCRs (Del I-VI) were 
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repeated. The PCR fragments showed no detectable differences in size 
compared to the previously conducted PCRs from the first passage of 
MVA-pp65/IE-1. Moreover, in Del III PCR the specific non-recombinant MVA 
PCR band (446 bp) was still absent (Fig. 6). 
MWM I II III IV  V  VI  C
fifth passage of MVA-pp65/IE-1
2,322 bp-
4,361 bp-
872 bp-
603 bp-
310 bp-
Fig. 6: PCR assay of fifth passage of MVA-pp65/IE-1 to check for stable
insertion of HCMV genes and stable MVA identity. PCR from viral DNA after 5
times passaging in BHK was performed using specific oligonucleotide primers for
deletion I-VI (I -VI). Molecular weight marker (MWM); Control PCR without DNA (C).
 
These results confirmed the correct insertion of HCMV genes into Del III for any 
virus used in this study (Fig. 5a). In addition, integrity, stability, and purity of the 
first and fifth passage of MVA-pp65/IE-1 was verified (Fig. 5b, left and 6). 
1.2. MVA-pp65/IE-1 stably expresses a fusion of the two HCMV antigens 
Modifications of the nucleotide sequences encoding for proteins, as e.g. the 
deletion of some parts, may strongly influence the secondary and tertiary 
structure of the produced proteins. Hence, all HCMV-MVAs used in this study 
were verified for protein expression. 
1.2.1. Western blot analysis of the first passage of MVA-pp65/IE-1 
Western blot experiments were carried out to detect expression of pp65 and IE-1 
on BHK infected with recombinant HCMV-MVAs at an MOI of 5. After 24 h, 
MVA-infected cell lysates were developed by Western blot using anti-IE-1, 
anti-pp65, anti-C7L, and anti-GAPDH antibodies. Proteins were visualized and 
VACV protein C7L (18 kDa) and GAPDH (36 kDa) confirmed the presence of 
viral DNA as well as cellular material in each sample (Fig. 7). 
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HCMV-specific antibodies detected a specific protein band of 72 kDa (Fig. 7: lane 
3) and 65 kDa (Fig. 7: lane 5) in MVA-IE-1 and MVA-pp65 infected cell lysates, 
respectively. Additionally, three fainter bands of lower weight, between 20 and 
50 kDa, were detected in MVA-pp65-infected cell lysates. 
Fig. 7: Verification of HCMV gene expression in recombinant MVA. BHK were
infected with viruses as indicated. Cells were harvested 24 h p.i. and protein lysates were
analyzed by Western blotting. Multichannel image of fluorescent blot and
chemiluminescent blot images is shown. Molecular weight marker (MWM).
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Noteworthy, a prominent protein band of approximately 120 kDa was detectable 
by immunoblot after infecting BHK with MVA-pp65/IE-1 (Fig. 7). Moreover, three 
fainter bands of smaller size (100 kDa, 80 kDa, 65 kDa) as well as similar bands 
compared to MVA-pp65 infected cell lysates (between 20 and 50 kDa) were 
detected. 
1.2.2. Western blot analysis of the fifth passage of MVA-pp65/IE-1 
The genetic stability of MVA-pp65/IE-1 was examined since earlier studies using 
MVA as viral vector showed genetic instabilities of recombinant MVA in rare 
cases (WYATT et al., 1996; WYATT et al., 2009). Hence, MVA-pp65/IE-1 was 
passaged five times in BHK, thirty single plaques were collected and each plaque 
was amplified on BHK for 96 h, before Western blots were performed using 
anti-IE-1, anti-GAPDH, and anti-C7L to visualize protein expression. The results 
confirmed the stable expression of the HCMV fusion gene by MVA-pp65/IE-1. 
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Fig. 8: Verification of stable HCMV gene expression in fifth passage of
MVA-pp65/IE-1. BHK were infected with single plaques (1-30) of the fifth passage of
MVA-pp65/IE-1. Cells were harvested 96 h p.i. and protein lysates were analyzed by
Western blotting. A cell-lysate of BHK infected with the first passage of MVA-pp65/IE-1 for
24h served as positive control (Pos.). Non infected cells (C). Molecular weight marker
(MWM). Figure shows one representative Western blot of ten plaques (11 to 20).
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The HCMV-specific protein was still present in 90% of the amplified and tested 
MVA-pp65/IE-1 virus single plaques. However, 3 out of 30 Western blot samples 
(plaque no. 1, plaque no. 14, and plaque no. 27) showed different results. In 
these cases, the HCMV fusion protein was missing and a specific 75 kDa protein 
band appeared instead (Fig. 8). 
These data indicate that MVA-pp65/IE-1, although missing 25 C-terminal amino 
acids and amino acid 421 to 475 of the HCMV IE-1 sequence, is able to 
efficiently and stably express the pp65/IE-1 fusion protein in BHK. 
1.3. Multi-step growth kinetics of recombinant HCMV-MVAs 
Before using recombinant MVA in immunotherapy or as a vaccine some 
important requirements have to be fulfilled.  
Among others, these include the verification that the recombinant MVA has not 
increased its hazard potential and not changed its limited replicative host range. 
These two conditions are also important to ensure that the recombinant MVAs 
can still be handled under biosafety level 1 conditions as non-recombinant MVA 
(ZKBS, 1997). 
One very important property of MVA is its inability to productively grow in human 
cells (MAYR & MUNZ, 1964; SUTTER & MOSS, 1992; CARROLL & MOSS, 
1997; BLANCHARD et al., 1998). Therefore, the following experiment examined 
the ability of MVA-IE-1, MVA-pp65, and MVA-pp65/IE-1 to replicate in human 
cells by performing multi-step growth analysis in HaCaT, an established 
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laboratory human cell line. During a total infection period of 3 days, none of the 
tested recombinant MVA was able to propagate in HaCaT (Fig. 9).  
Fig. 9: Multi-step growth kinetics of recombinant MVA. CEF () or HaCaT ()
cells were infected with MVA, MVA-IE-1, MVA-pp65 or MVA-pp65/IE-1 at an MOI of
0.01. Samples were collected at times as indicated and titrated on CEF cells. Figures
represent mean of two independent experiments. Hours post infection (hpi).
hpi
P
F
U
/m
l
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
0 4 12 24 48 72
hpi
P
F
U
/m
l
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
0 4 12 24 48 72
hpi
P
F
U
/m
l
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
0 4 12 24 48 72
hpi
P
F
U
/m
l
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
0 4 12 24 48 72
MVA MVA-IE-1
MVA-pp65 MVA-pp65/IE-1
 
Moreover, the amplification capacity of MVA-pp65/IE-1, MVA-IE-1, and 
MVA-pp65 was checked in CEF cells. Here, replication of MVA is still possible. 
After 72 h, a 1,000 to 10,000 fold increase in virus titers was measured. The virus 
titer of each recombinant MVA was comparable to control MVA, indicating that 
replication capacity was not reduced.  
2. Immunological characterization of MVA-pp65/IE-1  
As expected, the previous molecular characterization showed that 
MVA-pp65/IE-1 productively grew in primary chicken cells, but was not able to 
replicate in human cells. Moreover, it was genetically stable, pure, and efficiently 
expressed the desired HCMV genes. In a next step, MVA-pp65/IE-1 was 
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immunologically characterized. 
Thereby, this study focused on the activation and expansion of HCMV-specific 
T cells, in particular CD8 T cells, because it has been shown that the cellular 
immune response plays a key role in the prevention of HCMV disease 
(QUINNAN et al., 1982). 
A straightforward approach to study this would be the infection of PBMC with 
recombinant MVA, followed by analysis of the expansion of HCMV-specific 
T cells in such a culture. Expecting an extensive literature on such protocols, 
surprisingly only one group could be identified that was using such an approach 
(LA ROSA et al., 2006). 
Following a modified protocol of La Rosa et al. 2006 for one experiment, we tried 
to reproduce in vitro expansion of HCMV-specific T cells. PBMC of 2 donors, A 
and B, were incubated with CpG-A (1 µg/ml, Miltenyi) and CpG-B (1 µg/ml, 
Metabion) for 3 days. Then, CpG-treated PBMC were infected with 
MVA-pp65/IE-1, MVA-IE-1, MVA-pp65, and MVA at an MOI of 5 for 6 h. After 5 h, 
MVA-infected PBMC were  -irradiated with 34 Gy (≙ 3400 rads) and plated as 
effector cells in a ratio of 1:2 with untreated PBMC as described in the protocol. 
Cells were checked for vitality at day 4, day 7, and day 10. Unfortunately, neither 
expansion of HCMV-specific T cells occurred as described by La Rosa et al. nor 
did many of the PBMC survive the indicated procedure resulting in a 0.5 fold 
decrease in total cell numbers after 10 days. 
Looking for an alternative method to test the potential of recombinant MVA to 
expand HCMV-specific T cells, we decided to infect an antigen-presenting cell 
type with the virus and then co-culture it together with the PBMC. We had an 
established CD40 B cells system available in our lab which offered two 
advantages for this setting. Firstly, it is possible to easily generate long-term 
proliferating B cell cultures by CD40 stimulation of PBMC from any donor of 
interest (WIESNER et al., 2008). Secondly, we already knew that peptide-loaded 
CD40 B cells are able to easily expand specific T cells from autologous PBMC 
(ZENTZ et al., 2007; WIESNER et al., 2008). 
Thus, we had to ensure that infecting CD40 B cells with recombinant MVA results 
in antigen presentation to T cells. For this purpose, CD40 B cells were generated 
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from five suitable HCMV-positive donors as described in Section III.5.5. 
In a preliminary experiment, CD40 B cells were infected with the recombinant 
HCMV-MVAs at a range of different MOIs (0.1-5). Higher MOIs tended to be toxic 
for CD40 B cells, but a low MOI of 0.1-0.5 led to a satisfactory rate of infection 
(data not shown). Thus, an MOI of 0.5 was used for activation of IFN- -producing 
HCMV-specific polyclonal T cells after co-incubation with MVA-infected 
CD40 B cells and an MOI of 0.2 in the following experiments.  
2.1. Verification of the absence of EBV infection in CD40 B cells  
Epstein-Barr virus (EBV) is present in peripheral B cells of most healthy donors at 
a frequency of 1 virus in 104 to 106 B cells (BABCOCK et al., 1998) and may be 
reactivated and spread in a B cell culture (RICKINSON et al., 1984). Thus, most 
but not all CD40-stimulated B cell cultures from healthy donors are free of EBV 
infection (WIESNER et al., 2008). 
Before using the generated CD40 B cells in the experiments that follow, we 
needed to ensure that the cultures were free of EBV, in order to avoid any 
interference by reactivation of EBV-specific T cells.  
Therefore, all CD40 B cells used in this study were routinely verified for the 
absence of EBV-specific DNA sequences (glycoprotein 85, gp85). A dual PCR 
was performed where GAPDH and gp85 oligonucleotide primers were applied to 
detect the presence of human DNA and EBV DNA sequences, respectively. As 
shown in Fig. 10, PCR fragments specific for GAPDH sequences of 152 bp could 
be visualized in all PCR samples except the negative control (with water instead 
of DNA). The gp85-specific PCR band (461 bp) was only detectable in the 
positive control, DNA from an EBV-infected cell line, and was absent from all 
tested CD40 B cells. These observations confirmed that none of the used 
CD40 B cells were infected with EBV. 
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Fig. 10: Verification of the absence of EBV infection in CD40 B cells. B cells were
tested for the absence of EBV using dual PCR. Molecular weight marker (MWM). DNA
of EBV-infected lymphoblastoid cell line (Pos.). Control without DNA (C).
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2.2. Activation of IFN- -producing HCMV-specific polyclonal T cells after 
co-incubation with MVA-infected CD40 B cells 
To detect presentation of HCMV antigens on the surface of MVA-infected 
CD40 B cells, HCMV-specific T cells were required. Since these are present in 
HCMV-positive donors at considerable high frequency, polyclonal T cell lines 
containing a high proportion of HCMV-specific T cells can be prepared by a 
single round of stimulation with HCMV antigen-derived peptides (MOOSMANN et 
al., 2010). 
Autologous polyclonal T cells were generated from PBMC of donors A and B by 
stimulating them with the peptides VLE, ILE, NLV, CRV, or RPH for 10 days. 
Thereafter, they served as effector cells to determine whether CD40 B cells are 
able to present recombinant HCMV antigens delivered by recombinant MVAs. To 
achieve that, polyclonal T cell lines were co-cultured with MVA-infected B cells 
and IFN-  secretion was measured as readout for T cell activation.  
Fig. 11 shows the results of this experiment. In order to cover a broader range of 
epitopes, PBMC of 2 donors who differed in their HLA restriction (donor A, A1/A2 
B8/B60; donor B, A3/A28 B7/B63) were selected. Although the T cell lines were 
only short-term cultivated and specific T cells had not been purified, background 
reactivity was very low in 4/5 cultures. In one T cell culture (CRV), there was a 
higher background, but it was still an order of magnitude below recognition of 
HCMV antigens. Hence, the interpretation of the results was not impaired. 
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Fig. 11:  IFN- detection of activated HCMV-specific polyclonal T cells by MVA-
infected CD40 B cells. (A,B) Polyclonal T cells were generated by stimulation of
PBMC with HCMV peptides as indicated in headlines for 10 days. B cells were infected
with MVA, MVA-IE-1, MVA-pp65, or MVA-pp65/IE-1 and incubated with autologous
specific T cells for 16-18 h. Concentrations of IFN- in supernatants were determined
using ELISA. Error bars indicate mean and range of triplicates in one experiment. (C)
x-fold activation was calculated by dividing the detected IFN- values of B cells +
MVA-pp65/IE-1 by the sum of B cells + MVA-IE-1 and B cells + MVA-pp65, each.
Dashed line indicates geometric mean of the indicated epitopes.
 
Both donors showed significantly higher IFN-  levels when CD40 B cells were 
infected with recombinant HCMV-MVAs compared to non-recombinant MVA or 
non-infected CD40 B cells. This indicates that CD40 B cells are well suited to 
present HCMV-specific antigens delivered by recombinant MVAs.  
Moreover, results of donor A showed that MVA-pp65/IE-1 infected CD40 B cells 
were best able to activate polyclonal T cells resulting in highest numbers of IFN-  
secretion (Fig. 11a). This was true for all three epitope-specific polyclonal T cell 
lines in this experiment.   
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MVA-pp65-infected CD40 B cells activated the NLV-specific polyclonal T cell line 
only. In addition, IFN-  secretion was 3-fold reduced compared to NLV-specific 
polyclonal T cells recognizing CD40 B cells that were infected with 
MVA-pp65/IE-1. When MVA-IE-1-infected CD40 B cells were incubated with 
either VLE- or ILE-specific polyclonal T cells, IFN-  secretion was 5-fold and 
2-fold reduced compared to CD40 B cells infected with MVA-pp65/IE-1, 
respectively.  
Results for donor B point into the same direction (Fig. 11b). Here, CRV- and 
RPH-specific polyclonal T cells were incubated with MVA-infected CD40 B cells. 
As expected, MVA-IE-1 infected CD40 B cells were only able to induce high 
amounts of IFN-  secretion of T cells with CRV epitope specificity but not RPH 
specificity. Conversely, MVA-pp65 infected CD40 B cells were able to activate 
RPH-specific polyclonal T cells but not CRV-specific T cells. Again, 
MVA-pp65/IE-1 represented the only virus activating both pp65- and IE-1 specific 
polyclonal T cells. The measured amounts of IFN-  secretion of RPH- and 
CRV-specific T cells were roughly comparable to those of single HCMV-MVAs 
(approximately 6,580 pg/ml vs. 6,070 pg/ml and 2,410 pg/ml vs. 4,080 pg/ml, 
respectively).  
Additionally, the x-fold activation capability of MVA-pp65/IE-1 was calculated 
compared to MVA-IE-1 and MVA-pp65, by dividing the amount of IFN-  using 
MVA-pp65/IE-1 by the sum of IFN-  levels using single-recombinant MVAs 
(Fig. 11c). Notably, MVA-pp65/IE-1 showed a 1.4-fold activation potential on 
average compared to MVA-IE-1 and MVA-pp65 which ranged between 0.5-fold 
(CRV) and 3.3-fold (VLE) (Fig. 11c). 
Our data confirmed that HCMV-MVA-infected CD40 B cells efficaciously present 
HCMV epitopes to specific T cells. Therefore, they are a valuable tool for 
studying the functional properties of HCMV-encoding MVAs. Moreover, in most 
cases MVA-pp65/IE-1 showed the best activation potential of all viruses.  
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2.3. MVA-pp65/IE-1 efficiently propagates HCMV-specific CD8 T cells in 
PBMC of seropositive donors 
After proving the ability of CD40 B cells to present HCMV antigens encoded by 
MVA, they were used to examine the immunological effect of MVA-pp65/IE-1 in 
PBMC of CMV seropositive donors.  
PBMC from donors A and B were co-cultured with either MVA-pp65/IE-1 or 
MVA-infected CD40 B cells for 10 days. At days 0 and 10, HCMV-specific 
CD8 T cells of various epitope specificities were quantified by HLA/peptide 
multimer staining. At least one suitable epitope per antigen and donor was 
evaluated. For donor A, HLA-A2- and B8-restricted epitopes were studied, for 
donor B epitopes that were HLA-B7- and HLA-C7-restricted. Exemplary FACS 
analysis are shown for donor A in Fig. 12. 
2.3.1. Donor A 
The proportion of T cells specific for each of the tested epitopes within PBMC 
was increased after 10 days of in vitro stimulation using MVA-pp65/IE-1-infected 
CD40 B cells. Among the three specificities studied, T cells with ELK specificity 
showed the lowest increase after stimulation (3.5 fold), whereas T cells specific 
for NLV were increased 10-fold and VLE-specific T cells 20-fold (Fig. 12 and 
Tab. 5). 
In contrast, absolute numbers of specific T cells in PBMC stimulated using 
control MVA remained stable or even decreased (Tab. 5). There was an 
approximately 2-fold increase in the proportion of ELK-specific T cells after 
control MVA stimulation. Since total T cell numbers decreased 3-fold in this 
condition, however, ELK-specific T cells decreased in absolute terms (Fig. 13a).  
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Fig. 12: Analysis of HCMV-specific CD8 T cells after co-culturing of PBMCs with
MVA-infected CD40 B cells. HCMV-specific T cells were identified by staining with
appropriate HCMV-specific HLA/peptide multimers in PBMCs on day 0 (left column) and
after 10-day co-culture with B cells infected with MVA (middle column) or infected with
MVA-pp65/IE-1 (right column). Cells were analyzed by flow cytometry. Cells without
multimer staining (Control).
Control
NLV (pp65)
A*02:01-PE
VLE (IE1)
A*02:01
 
 
Changes in absolute numbers of HCMV-specific T cells (Fig. 13a) and the 
specific expansion per epitope specificity for both MVA-pp65/IE-1- and 
MVA-stimulated PBMC were also calculated (Fig. 13c). The specific expansion 
was defined as the ratio of the absolute numbers of specific T cells on day 10 
and day 0. 
Furthermore, the total expansion factor of PBMC was determined by dividing the 
total cell number of day 10 by the initial cell number at day 0 (Tab. 5). Since the 
total cell number after stimulation using MVA-pp65/IE-1 resembled the number of 
cells used to initiate the culture, for donor A the absolute increase in specific 
CD8 T cells was approximately parallel to their relative increase (Fig. 13). In 
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cultures stimulated with MVA, HCMV-specific absolute cell numbers stagnated or 
dropped as expected. 
 
donor A 
 
% multimer positive cells in CD8 T 
cells % CD8 T cells 
in total 
total 
expansion 
factor  
d0d10 
NLV VLE ELK 
PBMC d0 w/o virus 0.67 0.26 0.28 23.9 
PBMC d10 + MVA 0.57 0.59 0.64 39.0 0.3 
PBMC d10 + MVA-pp65/IE-1 6.50 5.39 0.97 86.6 1.1 
donor B 
                               
% multimer positive cells in CD8 T 
cells 
% CD8 T cells 
in total 
total 
expansion 
factor  
d0d10 
TPR RPH CRV 
PBMC d0 w/o virus 1.52 2.65 3.42 23.2 
PBMC d10 + MVA 1.26 2.87 8.89 32.4 0.4 
PBMC d10 + MVA-pp65/IE-1 5.89 12.11 22.28 79.1 1.5 
Tab. 5: Percentage of HCMV-specific CD8 T cells after co-culturing of PBMC (donor
A and donor B) with MVA and MVA-pp65/IE-1 CD40 B cells. HCMV-specific T cells
were identified by staining with appropriate HCMV-specific HLA/peptide multimers and
analyzed by flow cytometry.
 
2.3.2. Donor B 
The HLA/peptide multimers used to stain HCMV-specific T cells from donor B 
included the multimer CRV/C*07:02. HLA-C*07:02 is a ligand for the killer Ig-like 
receptor KIR2DL2/3 (PARHAM, 2005; MOESTA et al., 2008), which can be 
expressed by some CD8 T cells. Therefore, it is possible that peptide/HLA-
C*07:02 multimers may not only stain CD8 T cells with the matched 
antigen-specific T cell receptor (TCR), but also NK cells and some CD8 T cells 
that do not express the specific TCR. To exclude such CD8 T cells from our 
analysis, PBMC stained with HLA-C*07:02/CRV-streptamer were additionally 
counterstained with an anti-KIR2DL2/3 antibody and KIR2DL2/3-positive cells 
were excluded from analysis of CRV-specific T cells. As a consequence, 
potentially existing CD8 T cells that were both specific for CRV/C*07:02 and 
expressing this KIR were also subtracted from the analysis, which leads to an 
underestimation of the frequency of CRV-specific T cells. This is not a severe 
limitation, however, since KIR2DL2/3 is expressed only on a minority of T cells 
that were stained with the HLA-C*07:02/CRV-streptamer (Fig. 14). 
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Fig. 13: Propagation of HCMV-specific T cells after MVA-pp65/IE-1 infection.
HCMV-specific CD8 T cells were identified by HLA/peptide multimer staining. (A,B)
Absolute numbers of HCMV-specific T cells were calculated by multiplying total cell number
and the proportion of specific cells identified by multimer staining. Unstimulated PBMC (d0);
PBMC stimulated with CD40 B cells infected with MVA or MVA-pp65/IE-1 (d10). (C,D)
Specific expansion was calculated by dividing specific cell numbers on day 10 by cell
numbers on day 0. Figures show results of donor A (panel A, panel C) and donor B (panel
B, panel D).
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Interestingly, T cells with CRV specificity were consistently detectable as two 
distinct populations in donor B (Fig. 14). This phenomenon was most impressive 
in PBMC after stimulation using MVA-pp65/IE-1 for 10 days. This suggests that 
CRV-specific T cells from this donor consist of at least two subpopulations that 
differ either in their level of TCR expression or in TCR avidity to the CRV/C*07:02 
complex. The second possibility is more likely, since similar observations have 
been made for other HCMV epitopes before (PRICE et al., 2005). Similarly to 
donor A, relative numbers of epitope-specific T cells unambiguously increased 
under the condition of MVA-pp65/IE-1 stimulation in donor B, whereas in the 
control condition (MVA) proportions of specific T cells stagnated for two epitopes 
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(TPR, (WILLS et al., 1996) and RPH), but increased for one epitope (CRV) 
(Tab. 5). As explained before for donor A, this relative increase in some specific 
T cells in the control condition did not corresponded to an absolute increase of 
T cells specific for this epitope (Fig. 13b and d).  
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Fig. 14: Analysis of CRV-specific CD8 T cells after co-culturing of PBMC with
MVA-infected CD40 B cells. (A) PBMC on day 0 (left column) and after 10-day
co-culture with B cells infected with MVA (middle column) or infected with MVA-pp65/IE-1
(right column) were counterstained with anti-KIR2DL2/3 antibody and "KIR-negative"
gated to reduce background. (B) CRV-specific T cells were identified by staining with
HLA-C*07:02/CRV streptamer-PE. Cells were analyzed by flow cytometry. Cells without
HLA-C*07:02/CRV streptamer-PE staining (Control).
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Taken together, the results (presented for two donors, Fig. 13) showed that 
antigen-specific T cells to various epitopes of IE-1 and pp65 could be expanded 
using recombinant MVA-infected B cells, but not wildtype MVA. 
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This shows that MVA-pp65/IE-1 drives antigen-specific expansion of 
virus-specific T cells, an important prerequisite for the development of an HCMV 
vaccine.  
2.4. MVA-pp65/IE-1 has an at least comparable ability to propagate 
HCMV-specific T cells as MVA-IE-1 and MVA-pp65 
The next step was the comparison of MVA-pp65/IE-1’s stimulatory capacity to 
single HCMV-MVAs coding for either pp65 or IE-1.  
This time, PBMC from three HLA-A2-positive donors C-E were co-cultured for 
10 days with B cells that were infected with MVA-pp65/IE-1, MVA-IE-1, 
MVA-pp65, or control MVA. Having in mind that the number of cells under the 
condition of control MVA decreased in the previous experiment, a higher number 
of PBMC was stimulated with control MVA than with recombinant MVA encoding 
HCMV antigens for each donor, C-E (40   106, 28   106, and 16   106 PBMC, 
respectively). 
For stimulation with HCMV antigen encoding MVAs, lower numbers of PBMC 
were used (donor C-E, 16 × 106; 12-16 × 106, and 8-12 × 106 PBMC, 
respectively) according to availability. Constant T cell ratios per reaction volume 
were used throughout. 
The study focused on HCMV specific CD8 T cells with VLE, NLV, and IPS 
(GAVIN et al., 1993) specificities and quantified them by HLA/peptide multimer 
staining on day 0 and day 10, respectively. At least one suitable epitope per 
donor was evaluable. For donors C and D, HLA-A2 restricted epitopes (VLE, 
NLV) were studied. For donor E, HLA-A2 and HLA-B35 epitopes (VLE, NLV, 
IPS). 
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Tab. 6: Percentage of HCMV-specific CD8 T cells after co-culturing of PBMC
(donor C - B) with MVA, MVA-IE-1, MVA-pp65, and MVA-pp65/IE-1 CD40 B cells.
HCMV- specific T cells were identified by staining with appropriate HCMV-specific
HLA/peptide multimers and analyzed by flow cytometry.
 
donor C 
% multimer positive cells 
in CD8 T cells % CD8 T cells 
in total 
total expansion 
factor 
d0d10 
NLV VLE 
PBMC d0 w/o virus 0.31 0.16 30.9 
PBMC d10 + MVA 0.49 0.23 22.3 0.4 
PBMC d10 + MVA-IE-1 0.17 10.0 41.7 0.7 
PBMC d10 + MVA-pp65 51.4 0.06 52.4 0.9 
PBMC d10 + MVA-pp65/IE-1 28.0 12.25 57.0 1.5 
donor D 
VLE 
% CD8 T cells 
in total 
total expansion 
factor 
d0d10 PBMC d0 w/o virus 1.84 13.9 
PBMC d10 + MVA 1.83 18.5 0.5 
PBMC d10 + MVA-IE-1 39.1 47.0 1.1 
PBMC d10 + MVA-pp65 0.41 44.5 1.0 
PBMC d10 + MVA-pp65/IE-1 19.8 51.8 1.2 
donor E 
NLV VLE IPS 
% CD8 T cells 
in total 
total expansion 
factor 
d0d10 PBMC d0 w/o virus 0.34 0.10 0.40 13.3 
PBMC d10 + MVA 0.62 0.17 0.81 17.6 0.8 
PBMC d10 + MVA-IE-1 0.56 9.65 0.51 26.2 0.3 
PBMC d10 + MVA-pp65 36.6 0.11 11.2 77.1 3.1 
PBMC d10 + MVA-pp65/IE-1 34.3 2.03 10.2 66.7 2.9 
 
In all of the three donors, the proportion of T cells specific for each of the tested 
epitopes within PBMC strongly increased during the 10 days of in vitro 
stimulation using MVA-pp65/IE-1 infected CD40 B cells. As expected, within 
PBMC stimulated using MVA-IE-1 only IE-1 specific T cells and within PBMC 
stimulated using MVA-pp65 only pp65-specific T cells unambiguously increased 
during stimulation, respectively. In contrast, relative proportions of all tested 
HCMV T cell specificities remained stable or decreased in PBMC stimulated 
using control MVA (Tab. 6). 
Corresponding results were obtained when comparing the calculated absolute 
cell numbers of each epitope’s specificity (Fig. 15a). Furthermore, an absolute 
increase in CD8 T cells was only detectable in PBMC stimulated using any of the 
recombinant HCMV-MVAs, but not control MVA (Tab. 6). 
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Fig. 15: Infection of PBMC with MVA-IE-1, MVA-pp65 and MVA-pp65/IE-1 to
propagate HCMV-specific T cells. HCMV-specific CD8 T cells were identified by
HLA/peptide multimer staining. (A) Absolute numbers of HCMV-specific T cells were
calculated by multiplying total cell number and proportion of specific cells identified by
multimer staining. Unstimulated PBMC (d0); PBMC stimulated with CD40 B cells infected
with the indicated MVA viruses (d10). (B) Specific expansion was calculated by dividing
specific cell numbers on day 10 by cell numbers on day 0. Error bars indicate mean and
range of two (NLV) or three (VLE) different donors.
 
Overall, the total expansion factor of PBMC stimulated using one of the 
recombinant HCMV-MVAs was higher compared to those stimulated using 
control MVA. The only exception was the MVA-IE-1-stimulated culture from 
donor E, who had a particularly low frequency of IE-1 specific (VLE-specific) 
T cells in PBMC (Tab. 6). 
Interestingly, only stimulation with MVA-pp65-IE-1-infected B cells, but not the 
three other MVAs, consistently increased total cell numbers in cultures from all 
three donors (total expansion factor: 1.2–2.9). 
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Comparing MVA-pp65/IE-1 and MVAs expressing single HCMV antigens, each of 
the recombinant HCMV-MVAs was similarly able to stimulate the corresponding 
HCMV-specific T cells within PBMC. This was true for absolute cell numbers of 
HCMV-specific T cells (Fig. 15a) and for specific expansion (Fig. 15b) of T cells 
with each of the different epitope specificities.  
These results confirmed that the immunological impact of MVA-pp65/IE-1 in 
stimulating HCMV-specific T cells within PBMC was at the same level as the 
impact of MVA-IE-1 and MVA-pp65, respectively. Potentially, an MVA coding for 
a large fusion protein of two antigens might be less suitable for T cell stimulation 
than MVAs coding for single antigens, since competition of epitopes of MHC 
molecules or competition of T cells for MVA-infected antigen-presenting cells 
may take place. However, the present results showed that such deleterious 
effects were either absent in this situation, or were compensated by the improved 
construction of MVA-pp65/IE-1. 
2.5. IFN-γ secretion by HCMV IE-1-specific T cells generated with 
recombinant HCMV-MVAs 
As we were not only interested in the stimulation capability of the recombinant 
HCMV-MVAs but also in their functional behavior, reactivity of the previously 
generated HCMV-specific T cells was studied within PBMC of donors C and D. 
We examined whether those T cells were able to recognize CD40 B cells loaded 
with various IE-1 peptides. Responses to four different IE-1-specific epitopes 
were analyzed per donor, restricted through HLA-A*02:01, A*03:01, and B*40:01, 
by quantifying IFN-  secretion of HCMV-specific T cell lines in ELISPOT and 
ELISA assay. In parallel, ELISPOT assays with unstimulated PBMC were 
performed to estimate the increase of IE-1-epitope specific T cells during MVA 
stimulation (Fig. 16a and d). Both donor C and donor D showed lower fre-
quencies of HCMV-specific T cells than detected by multimer staining by a factor 
of three on average. Despite of this, the IFN-  ELISPOT remains a valuable 
assay, since it sensitively detects and quantifies an important antiviral effector 
function of virus-specific T cells. 
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Fig. 16: Propagation of HCMV IE-1-specific T cells from PBMC. Unstimulated PBMC
were incubated with HCMV IE-1 derived peptides (A and D) or PBMC stimulated using
recombinant MVAs were incubated with HCMV IE-1-peptide-loaded CD40 B cells ( B-C and
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(A-C) and donor D (D-F). Columns and error bars above indicate mean and maximum of
triplicates in one experiment.
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2.5.1. Donor C 
Surprisingly, a quite pronounced IFN-  secretion in PBMC stimulated under the 
condition of control MVA was measured in all tested IE-1-epitopes also in the 
negative control in both assays, ELISPOT (Fig 16b) and ELISA (Fig. 16c). These 
observations did not disturb the interpretation of the other results, as each set of 
epitope-loaded B cells was controlled by a separate negative control, B cells not 
loaded with peptide (Fig. 16, white columns). Potential reasons for this apparently 
B cell-specific background reactivity are discussed in Section V. 
HCMV-specific T cells in non-stimulated PBMC of donor C only recognized 
VLE- and ILE-, but not KEV- and TMY-peptide-loaded B cells (Fig. 16a). 
Furthermore, IFN-  secretion was 30- to 40-fold increased within PBMC 
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stimulated using MVA-pp65/IE-1, whereas in PBMC stimulated using MVA-IE-1 
an only 25-fold increase of cells recognizing VLE- and ILE-loaded B cells was 
detectable. As expected, HCMV-specific T cell lines stimulated using MVA-pp65 
failed to recognize any IE-1-peptide. Besides, T cells in PBMC stimulated using 
MVA-IE-1 also recognized KEV-loaded B cells by ELISPOT (Fig. 16b) but not in 
ELISA (Fig. 16c). 
Comparable results were obtained when measuring the IFN-  secretion in ELISA. 
Highest reactivity of T cells in PBMC stimulated using MVA-pp65/IE-1 and 
MVA-IE-1 was detected against VLE- and ILE-loaded B cells (Fig. 16c). As 
expected and already detected via ELISPOT, PBMC stimulated using MVA-pp65 
did not recognize IE-1 peptide loaded B cells. 
2.5.2. Donor D 
As analyzed by ELISPOT, HCMV-specific T cells in non-stimulated PBMC of 
donor D were again only able to recognize B cells loaded with peptides VLE and 
ILE, but not RIK and TMY (Fig. 16a).  
The ability of T cells in PBMC stimulated for 10 days by MVA-pp65/IE-1- and 
MVA-IE-1-infected CD40 B cells to recognize VLE- and ILE-loaded CD40 B cells 
was quite comparable in both assays (Fig. 16e and f). Moreover, RIK-loaded 
CD40 B cells were recognized from T cells of both stimulated PBMC in spite of 
their undetectable frequency ex vivo. Admittedly, the level of IFN-  secretion was 
not comparable to VLE- and ILE-loaded CD40 B cells, but obviously positive 
compared to TMY-loaded CD40 B cells and CD40 B cells without peptide. This 
time as expected, HCMV-specific T cell lines within PBMC stimulated using either 
MVA-pp65 or control MVA failed to recognize any of the IE-1-peptides presented 
by CD40 B cells. Taken together, functional T cell responses to various IE-1 
peptides were amplified by stimulation of PBMC with MVAs encoding IE-1 
individually or as a fusion protein with pp65. The absence of responses to the 
TMY peptide was not surprising, since responses to this peptide can be elicited in 
HLA-A2-transgenic mice, but are often absent in humans (ELKINGTON et al., 
2003). 
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V.  DISCUSSION 
For the past 40 years, intensive effort has been placed in developing a vaccine 
against HCMV which can cause lifelong problems and require expensive and 
toxic treatment of infected newborns and transplant recipients. In 2000, the U.S. 
classified the creation of an HCMV vaccine as a national priority (INSTITUTE OF 
MEDICINE, 2000). Although intensified research activities were catalyzed by this 
classification, the development of a satisfying vaccine has not been successful 
until now. 
This study evaluated a new HCMV-MVA vaccine candidate (MVA-pp65/IE-1) that 
had recently been constructed in our laboratory. This recombinant MVA 
expresses a fusion protein of the immunodominant antigens pp65 and IE-1. The 
construct has several novel features that were designed to optimize its potency. 
A detailed genetic and immunological characterization of MVA-pp65/IE-1 was 
performed. Thereby, the focus was to detail MVA-pp65/IE-1’s capacity to activate 
HCMV-specific CD8 T cells both quantitatively and functionally. Replication 
capacity of MVA-pp65/IE-1 in primary CEF cells proved to yield high titers (107 
PFU/ml) that were comparable to non-recombinant MVA. In contrast, 
MVA-pp65/IE-1 was unable to grow in human cells, as expected. Furthermore, 
this study confirmed that HCMV-MVA-infected CD40 B cells are well suited to 
effectively present HCMV-specific antigens to specific T cells. Moreover, 
antigen-specific T cells to various epitopes from IE-1 and pp65 could be 
expanded in vitro by stimulation with MVA-pp65/IE-1-infected B cells. Finally, 
IFN-  secretion of these T cells co-cultured with IE-1-loaded B cells was 
detectable. The expansion and functionality of virus-specific T cells and the 
consistent high cell numbers from tested donors achieved only when 
MVA-pp65/IE-1 was used. This indicated high immunogenicity and constituted an 
important prerequisite for the development of an HCMV vaccine.  
Taken together, these data support the usage of MVA-pp65/IE-1 as a promising 
vaccine candidate in patients undergoing immunosuppressive therapy.  
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Reasons for using a pp65/IE-1 fusion gene and the MVA vector platform for the 
construction of an HCMV vaccine  
We chose MVA as a vaccine platform because it is known to deliver foreign 
antigens with high stability to the host cell thus enabling an efficient 
antigen-specific immune response. Moreover, MVA constitutes an ideal 
candidate to immunize patients during immunosuppressive treatment due to its 
remarkable safety profile. Following well-established protocols for the generation 
of recombinant MVAs available in our lab, we included HCMV genes into the 
existing deletion site III of MVA’s genome and placed them under the control of 
the strong early-late promoter PmH5 (MEYER et al., 1991; WYATT et al., 1996; 
KREMER et al., 2012). Cytotoxic T cell responses are considered to play a 
crucial role in CMV infection and in CMV prevention (QUINNAN et al., 1982; 
REDDEHASE et al., 1987; RIDDELL et al., 1992). As HCMV antigens to be 
vaccinated against, we chose pp65 and IE-1, because they constitute two major 
targets of T cells and generally induce immunodominant responses (GIBSON et 
al., 2004; SYLWESTER et al., 2005). Moreover, T cells directed against these 
antigens are considered to play important roles in preventing primary infection 
and reactivation of HCMV, and the two antigens are complementary in this 
respect. Specifically, pp65 is an abundant structural protein of the tegument. 
Thus it offers the possibility of a fast processing and presentation to T cells 
during primary infection in recently infected cells (McLAUGHLIN-TAYLOR et al., 
1994), and pp65 is also abundant in the late phase of the replication cycle. In 
contrast, IE-1 is deemed to play a more important role in viral reactivation than 
pp65 because it is expressed earlier in HCMV replication (STINSKI et al., 1983). 
In our approach, we decided to combine both immunogenic antigens in the form 
of a fusion gene, because it is still unclear whether pp65- or IE-1-specific T cells 
are more important to prevent HCMV disease in transplant recipients. Some 
studies described IE-1-specific T cells to be most beneficial against HCMV 
(BUNDE et al., 2005; SACRE et al., 2008), whereas others showed that the 
presence or the transfer of pp65-specific T cells was associated with reduced or 
controlled HCMV disease (WALTER et al., 1995; GRATAMA et al., 2008). T cells 
have been targeted against each of the antigens during adoptive T cell transfer 
(COBBOLD et al., 2005; SCHMITT et al., 2011), but available data is too limited 
to clearly identify which antigen has superior protective capacity. The results of 
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recently completed controlled clinical studies on T cell transfer (BOECKH et al., 
2015), expected to be published soon, may provide more information on this 
open question. 
In contrast to other groups who used mixtures of single recombinant 
HCMV-MVAs encoding for either pp65 or parts of the IE-1 gene (WANG et al., 
2004), our approach with a single recombinant MVA encoding both genes offers 
the possibility to decrease the number of viral vectors required for an effective 
vaccination. Consequently, safer, more practical, and substantially more 
economic immunization of humans may be achieved through this approach. 
Wang et al. generated a single recombinant MVA vaccine including exon 4 of 
IE-1 (WANG et al., 2004) to avoid the transactivation properties of IE-1 
(CASTILLO & KOWALIK, 2002). However, exon 4 still contains a STAT2 binding 
region that may potentially decrease immunogenicity of the construct, since it 
interferes with the cellular interferon response (HUH et al., 2008). Perhaps 
elimination of elements with transactivation functions and abolition of nuclear 
targeting may decrease the likelihood of unwanted effects. Accordingly, we 
excluded the known NLS region encoded by exon 2 (LEE et al., 2007) and the 
STAT2 binding region from the IE-1 sequence used in the pp65/IE-1 fusion 
construct. Admittedly, by excluding these two regions, the remaining IE-1 
sequence is shorter than the complete exon 4. However, exon 3 encodes 
relevant T cell epitopes (KHAN et al., 2007), whereas the STAT2 binding region 
is dispensable as a source of epitopes (KHAN, 2007). In light of these 
modifications, we hypothesized for an improved immunogenicity of our pp65/IE-1 
fusion antigen. Moreover, our inclusion of exon 3 is proposed to increase antigen 
stability (HUH et al., 2008), which is a desired property for efficacious vaccination 
with MVA. 
Wang et al. constructed another HCMV-MVA with pp65 and exon 4 of IE-1 
separately placed into deletion site II of the MVA genome (WANG et al., 2007). In 
contrast, we investigated the construction of a fusion gene of pp65 and modified 
IE-1. A fusion gene offers several advantages including the simultaneous 
expression of its constituents, followed by joint uptake by APCs and antigen 
presentation. Moreover, a fusion gene is under the control of one promoter, and 
hence expression of the constituents is uniform. On the contrary, a construction 
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with 2 distinct genes – as e.g. in Wang et al. – requires a promoter for each gene 
which is potentially problematic. The use of two different promoters results in 
differences in the levels of gene expression, whereas a combination of two 
similar promoters introduces homologous nucleotide sequences and thus 
potential instability of the viral vector. Wang et al. solved this problem by using 
two synthetic promoters (Psyn I and Psyn II) for the generation of their 
HCMV-MVA. These promoters had already been frequently used in the 1990’s 
but are currently considered more rarely due to the synthesis of very high levels 
of recombinant gene products that may lead to a reduced replication capacity of 
the recombinant MVA (WYATT et al., 1996). Such replication deficiency is a 
disadvantage for large scale GMP production of any candidate vector vaccine. 
Therefore, we constructed our MVA-pp65/IE-1 using the current gold-standard 
promoter system, the strong early-late promoter PmH5 (WYATT et al., 1996). 
In general, the construction of a fusion gene bears a high risk of incorrect folding 
of the protein leading to instabilities. Furthermore, such synthetic fusion proteins 
might develop new unwanted properties, such as increased cytotoxic 
characteristics. In our studies, MVA-pp65/IE-1 did not show such unfavorable 
properties and remained stable over very long periods of time with no toxicity 
observed. Despite the fact that we were not the first group who constructed a 
fusion gene composed of pp65 and IE-1 (BERNSTEIN et al., 2009), our 
MVA-pp65/IE-1 encodes for a novel synthetic immunogen originated from pp65 
and IE-1 that is designed to optimize immunogenicity.  
MVA-pp65/IE-1 stably expresses its transgene and retains the specific safety 
properties of MVA 
Since earlier studies using MVA as a viral vector rarely observed genetic 
instabilities of recombinant MVA (WYATT et al., 1996; WYATT et al., 2009), the 
stable expression of the HCMV fusion gene by MVA-pp65/IE-1 was tested. The 
results showed that ∼90% single MVA-pp65/IE-1 plaques stably expressed the 
HCMV protein of interest after five passages in BHK. Moreover, Western blot 
analysis illustrated that the majority of the fusion protein was intact 48 hours after 
infection. 96 hours post infection, the majority of the fusion protein was cleaved, 
giving rise to a dominant 50 kDa band stained by an anti-IE-1 antibody, but the 
complete fusion protein remained detectable after this extended infection period. 
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This result showed that the intact pp65/IE-1 fusion protein is expressed for 
several days. This is an important prerequisite for the in vivo immunogenicity of 
this MVA vaccine candidate, since it was shown by Gasteiger et al. that cross-
presentation of MVA-encoded antigen may be the major mechanism leading to 
priming of antigen-specific T cells after MVA vaccination (GASTEIGER et al., 
2007). In contrast, destabilized MVA-expressed antigens prime specific T cells 
with much lower efficiency (GASTEIGER et al., 2007). 
The results of the multi-step growth analysis showed that important requirements 
for large scale MVA-pp65/IE-1 vaccine manufacturing are fulfilled. The growth 
kinetics confirmed that MVA-pp65/IE-1 did not productively grow in human cells. 
In addition, its amplification capacity in CEF was comparable to non-recombinant 
MVA (Fig. 9). This implies that MVA-pp65/IE-1 can be handled and produced 
under biosafety level 1 conditions (ZKBS, 1997).  
Immunological characterization of MVA-pp65/IE-1 
In the first approach to study the immunological effect of MVA-pp65/IE-1, we 
followed a modified version of the protocol described in La Rosa et al. 2006. We 
were not able to reproduce the authors’ results of an in vitro expansion of 
HCMV-specific T cells or a survival in PBMC. One potential reason for the lack of 
success is the high infectious dose of MVA recommended by La Rosa et al. (an 
MOI of 5). Perhaps different protocols were used to determine viral titers. 
Moreover, the quality of virus titers might be influenced by stock purification 
methods which could potentially differ along various lines: (1) the duration of virus 
amplification, (2) the type of cells used for amplification, (3) whether purification 
was performed using 36% sucrose gradient centrifugation or not, and (4) the 
method of resuspension of the final virus pellet (PBS supplemented with 5% 
lactose vs. 10 mM Tris-HCl, pH 9.0). Furthermore, purified MVA loses some of its 
infectivity when stored at -20°C and not at -80°C. This is another potential 
explanation for the higher MOIs necessary for sufficient infection rates in the 
earlier study (LA ROSA et al., 2006). For that purpose, all recombinant MVAs 
used in this study were stored at -80°C and the virus was strictly handled on ice 
until usage; thus ensuring the stability of the virus titer. This goes in line with the 
observation that a much lower MOI of 0.1 to 0.2 led to robust infection, T cell 
activation, and expansion in all experiments that were performed thereafter, and 
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led to better survival of infected cells. 
Induction of IFN- -secretion of HCMV-specific polyclonal T cells after 
co-incubation with MVA-infected CD40 B cells 
After confirming that CD40 B cells were well suited to efficaciously present 
HCMV-specific antigens delivered by recombinant MVAs to specific T cells, this 
method was used to study the functional properties of HCMV-encoding MVAs in 
greater detail. Remarkably, MVA-pp65/IE-1-infected CD40 B cells were best able 
to activate polyclonal T cells, resulting in the highest numbers of IFN-  secretion 
for all epitopes tested of donor A when this virus was used (Fig. 11a). For 
donor B, the activation potential was more comparable to single HCMV-MVAs 
(Fig.11b). On average, MVA-pp65/IE-1 showed the best activation potential of all 
studied viruses when evaluating the functional properties of different recombinant 
HCMV-MVAs (Fig. 11c). Furthermore, only stimulation with 
MVA-pp65/IE-1-infected B cells, but not the three other MVAs, consistently 
increased total cell numbers in cultures from all three donors (total expansion 
factor: 1.2–2.9, Tab. 6). This data gave the indication of a potential increase in 
immunogenicity due to the unique modifications of the IE-1 gene sequence. 
In addition, the possibility of immunomodulatory effects of pp65 needed to be 
considered, since an initial report described that pp65 is able to reduce 
presentation of IE-1 (GILBERT et al., 1996). However, it appears that these early 
results were never replicated, and recent studies did not confirm them, but found 
no undesirable effect of pp65 on IE-1 presentation and T cell activation 
(AMERES et al., 2013). Negative effects were also absent within these studies. 
This is also consistent with the finding of Wang et al., who used MVAs encoding 
two separate genes within one virus (WANG et al., 2007), as well as with this 
study using an MVA encoding for one fusion gene composed of pp65 and 
modified IE-1. 
Expansion of HCMV-specific T cells in PBMC of donors A and B by stimulation 
with MVA-pp65/IE-1-infected B cells compared to B cells infected with control 
MVA was closely monitored by HLA/peptide multimer staining. Distinct 
populations of antigen-specific T cells were detected for all epitopes analyzed 
(donor A and B). The observation that CRV-specific T cells were detectable as 
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two distinct populations in PBMC after stimulation using MVA-pp65/IE-1 suggests 
that CRV-specific T cells from donor B consist of at least two subpopulations that 
most probably differ in their TCR avidity to the CRV/C*07:02 complex (Fig. 14). 
This data is analogous to Price et al. who described oligoclonal CD8 T cell 
responses against the NLV-epitope. They observed a general dominance of one 
or two prevalent clonotype responses against NLV that differed in multimer 
staining intensity and correlated with avidity (PRICE et al., 2005). Data on 
clonotypic composition of CRV/C*07:02-specific T cells have not been published, 
but unpublished data indicate that these T cells have a highly complex TCR 
repertoire (Liang and Moosmann, personal communication), which may explain 
the variability of multimer staining. 
Interestingly, staining PBMC and T cell lines with the CRV/HLA-C*07:02 multimer 
resulted in different subpopulations while this was not the case with the 
NLV/HLA-A*02:01 multimer. A probable explanation for this might be the high 
concentration of multimers that were used throughout this experiment. Price et al. 
who found that the subpopulations with low intensive multimer staining by 
multimers increased only under lower multimer concentrations. However, at least 
CRV-specific T cells appeared as two subpopulations in flow cytometry indicating 
that they might differ in their avidity. The property of MVA-pp65/IE-1-infected 
B cells to stimulate clonotypic diversity within HCMV-specific T cells should be 
considered as an additional advantage in counteracting complex pathogens, e.g. 
HCMV. 
In general, an MVA coding for a large fusion protein of two antigens might harbor 
the danger that competition of epitopes of MHC molecules or competition of 
T cells for MVA-infected antigen-presenting cells may take place. However, this 
data showed no decrease in efficacy of antigen presentation through MVA 
presenting the fusion protein (Fig. 13 and 15). This finding either indicates that 
MVA-pp65/IE-1 is able to compensate these effects by its improved construction, 
or competition effects were absent. Therefore, MVA-pp65/IE-1 effectively induces 
immune responses as the corresponding single recombinant HCMV-MVAs, and 
can be considered a promising HCMV vaccine candidate.  
Considering that cross-presentation is a major pathway for CD8 T cell priming in 
vivo (GASTEIGER et al., 2007), it is very unlikely that following vaccination the 
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amount of antigen available for cross-presentation will be high enough to give 
rise to competition for MHC binding in the cross-presenting cell. 
As for the other donors, HCMV-specific T cells from donor C could be specifically 
expanded by stimulation with HCMV antigen-encoding MVAs. Surprisingly, 
PBMC of donor C stimulated under the condition of non-recombinant (control) 
MVA showed a pronounced, but unspecific IFN-  secretion (Fig. 16b and c). The 
most probable explanation for this result is that peptide-loaded B cells 
propagated other, but non-HCMV-specific T cells in this setting due to the lack of 
HCMV-specific antigens. These conditions might enable the propagation of 
T cells against irrelevant antigens of different origin. Likely, these include 
auto-reactive T cells that are specific for (presently unknown) autoantigens on 
activated B cells. In the presence of viral antigens that are recognized by 
virus-specific T cells from the donor, such autoreactive T cells are suppressed or 
lost due to competition, but in the absence of stimulation of virus-specific T cells 
the autoreactive T cells may expand (Moosmann, personal communication). 
Moreover, T cells with FCS-antigen specificities also might be propagated 
because the cell culture medium is supplemented with FCS. Lastly and less 
likely, T cells specific for murine antigens might have an influence since the 
B cells were cultured on LL8, a murine cell line. These observations are similar to 
earlier findings that stimulation with LCLs (EBV-transformed B cells) may activate 
T cells specific for self-antigens expressed by activated B cells (ADHIKARY et 
al., 2007; LINNERBAUER et al., 2014). Although their physiological origin and 
function is not clear, such B cell autoreactive T cells do not seem to be 
problematic in clinical application, since LCL-stimulated T cells have been safety 
used for EBV-specific T cell therapy in more than 100 patients in the absence of 
major toxicity (HESLOP et al., 2010). 
The amino acid sequences of T cell epitopes from HCMV antigens may differ 
according to the HCMV strain. This is particularly relevant for IE-1, which is less 
conserved between HCMV strains than pp65. Thus, there are polymorphisms in 
several immunodominant CD8 T cell epitopes in IE-1, notably the epitopes 
VLE/ILE (Tab. 3), CRV, and ELR/ELK. However, the intensity of IFN-  T cell 
responses against VLE- or ILE- peptide-loaded B cells did not differ when using 
either MVA-IE-1 (AD169) or MVA-pp65/IE-1 (TB40E) for PBMC stimulation, 
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although these strains differ in their IE-1 gene sequence ( e.g. regarding the 
epitope VLE in AD169 and ILE in TB40E) (Fig. 16). The initial values of VLE- and 
ILE-specific T cells in PBMC at day 0 analyzed by ELISPOT did not appear to 
influence this observation. Indicating none or only a minor influence of 
epitope-variations, these findings generally support the view that a sufficient 
proportion of T cells specific for such polymorphic epitopes are able to recognize 
both variants of the epitope. Therefore, it is likely that MVA-pp65/IE-1 can be 
used to prevent disease caused by different HCMV strains. Admittedly, a high 
peptide concentration (5 µg/ml) was used for recognition of peptide-specific 
T cells in this assay which might have activated T cells with VLE-specificity by 
ILE-loaded B cells, although they have a lower affinity to the ILE- than to the 
VLE-peptide, and vice versa. Thus, the present analysis is not definitive, and 
further analyses of MVA-expanded HCMV-specific T cells should be performed 
that address the question more specifically, either by using target T cells loaded 
with the different polymorphic versions of the peptides at limiting dilution, or by 
employing titratable gene vectors that code for individual polymorphic HCMV 
epitopes. 
Our data did not report T cell responses to the TMY peptide although it has been 
reported that TMY-specific responses can be elicited in HLA-A2-transgenic mice 
(GALLEZ-HAWKINS et al., 2003). Our finding is not surprising as it corresponds 
to other studies that showed an absence of these responses in humans as well 
(ELKINGTON et al., 2003). The reasons for this different epitope being used in 
humans and mice are not well understood. However, it is possible that some 
HCMV-specific T cells might be missing in humans that are present in mice due 
to negative selection, as both organisms have different endogenous protein 
repertoires. Moreover, it might be that the murine and human proteasomes differ 
in antigen processing. Hence, not the same epitope repertoire is presented to 
T cells with matching epitope specificity in HLA-A2-transgenic mice and humans. 
The literature described KEV and RIK as further epitopes of IE-1 that could only 
be observed in some but not in a majority of humans (KHAN et al., 2007; 
AMERES et al., 2013). When examining these epitopes using MVA-pp65/IE-1, 
RIK-specific responses could only be partially detected while KEV-specific 
responses were absent. An analysis of a larger number of donors would clarify 
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whether T cells specific for these epitopes can be expanded from every donor 
who carries these specificities. So far, we could not obtain evidence that 
HCMV-specific T cells could not be expanded in such a situation. 
This indicates that MVA-pp65/IE-1 is not only able to stimulate HCMV-specific 
T cells within PBMC, but that they also have functional reactivity properties. 
These important observations further confirmed that MVA-pp65/IE-1 is a 
promising vaccine candidate against HCMV. The interesting observation, that 
only stimulation of PBMC (donor C-E) with MVA-pp65-IE-1-infected B cells, but 
not the three other MVAs, consistently increased total cell numbers (total 
expansion factor: 1.2-2.9, Tab. 6) implies a potential advantage in 
immunogenicity of this promising vaccine candidate.  
Further avenues of research/next steps 
Within this study, the immunological characterization of MVA-pp65/IE-1 was 
primarily conducted by evaluating CD8 T cells. In order to include all different cell 
types of the cellular immune response that are important in the recovery of 
HCMV disease (BIRON et al., 1989; GABANTI et al., 2014), CD4 T cells as well 
as NK cells should also be part of the examination in further experiments. 
Before MVA-pp65/IE-1 may reach clinical trials, it requires further preclinical 
characterization. A potential intermediate step towards this would be the usage of 
HLA-A2-transgenic mice, an in vivo model that allows for the evaluation of 
HCMV-specific T cell responses.  
In general, it is difficult to find an appropriate animal model to test the efficacy of 
HCMV vaccines, as a challenge model of HCMV is not feasible due to the very 
strict host specificity of CMV. Nonetheless, several different animal models partly 
resemble the HCMV infection in humans. Firstly, a lot of important research on 
CMV was conducted by studying the murine cytomegalovirus (MCMV) in mice 
(REDDEHASE et al., 1985; MUTTER et al., 1988). Moreover, using guinea pigs 
to study the guinea pig cytomegalovirus (GPCMV) seems to be the most 
promising model to evaluate the transmission of CMV to the fetus during 
pregnancy by crossing the placenta because this animal model is very similar to 
humans (SCHLEISS et al., 2015). Most notably, rhesus cytomegalovirus 
(RhCMV) disease in non-human primates is consided to be the animal model 
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most comparable to HCMV disease in humans (YUE et al., 2008), but 
nevertheless findings in this model are still not fully transferable. Thus, a fully 
satisfying animal model is lacking for the evaluation of a successful vaccine to 
prevent HCMV disease. 
Encouraged by the in vitro data collected concerning MVA-pp65/IE-1 and 
considering the convincing safety and immunogenicity of other recombinant MVA 
vaccines in preclinical trials, we are confident that the MVA-pp65/IE-1 vaccine 
candidate will perform well in in vivo experiments. 
Possible therapeutic uses of MVA-pp65/IE-1  
MVA-pp65/IE-1 offers several possible applications in humans. Firstly, 
MVA-pp65/IE-1 can be directly used for vaccination of patients before 
transplantation. Among patients who receive solid organ transplantation, 
seronegative recipients obtaining a transplant from a seropositive donor would 
benefit most from a vaccination before transplantation, because they could then 
build up immunity with HCMV-specific T cells before receiving an HCMV-positive 
organ during immunosuppressive therapy. In contrast, HCMV-positive recipients 
of HSC would profit most from a pre-transplantational vaccination of an 
HCMV-negative HSC donor, because grafts from such a donor are otherwise 
unable to reconstitute HCMV-specific immunity in the patient. Since HCMV 
reactivation in HSCT patients is also associated with graft-versus-host disease as 
well as transplant rejection, such a vaccine may have wide-ranging beneficial 
effects on transplantation success.  
An alternative use of MVA-pp65/IE-1 would be to employ it for in vitro 
amplification of HCMV-specific T cells before adoptive transfer to patients. Other 
approaches in adoptive immunotherapy obtain the HCMV-specific T cells of 
interest by staining of PBMC with multimers. This procedure is only able to 
enrich, not expand, those T cells and thus requires large numbers of PBMC. As 
confirmed in this study, MVA-pp65/IE-1 in combination with CD40 B cells 
efficiently stimulates HCMV-specific T cells after one round of stimulation. 
Admittedly, there are other ways to expand HCMV-specific T cells in vitro for 
adoptive T cell transfer such as complete HCMV viruses or adenoviral vectors 
encoding for HCMV genes (REUSSER et al., 1991; ZHONG et al., 2008). 
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However, compared to these approaches MVA vector vaccines do a better job in 
meeting GMP requirements and should thus be preferred. 
In the case of HCMV, another important task for a vaccine is to prevent the 
transmission during pregnancy. Remarkably, our MVA-pp65/IE-1 is a feasible 
backbone for including further major antigens to widen the scope of possible 
applications in pregnant women to prevent infection of the unborn child, as well 
as to improve its applicability in the case of transplant recipients even further. 
Thereby, the humoral immune response is especially important. As it is known 
that MVA is not only able to stimulate the cellular but also the humoral pathway 
by production of antigen-specific antibodies (SUTTER et al., 1994), this vector 
offers all requirements to also include antigens that are crucial for that. In this 
context, the gH/gL/UL128/UL130/UL131A is a pentamer complex known for its 
importance in entering endothelial as well as epithelial cells (WANG & SHENK, 
2005; RYCKMAN et al., 2008). Antibodies against this pentameric glycoprotein 
appear to be superior in neutralization of infection (CHIUPPESI et al., 2015). 
Therefore, this complex could potentially be added to the MVA-pp65/IE-1 
backbone. This improvement of the MVA-pp65/IE-1 would widen the scope of the 
vaccine even further, since a combined virus would induce CD8 T cells, 
CD4 T cells, and neutralizing antibodies. This would be favorable for its 
application in pregnant women.  
To further improve the use of MVA-pp65/IE-1 in the case of transplantation 
recipients, a selection of major antigens of the various infectious agents that are 
harmful for transplant patients could be combined into one MVA vector (e.g. 
HCMV, EBV, adenovirus). Efforts to cover many of those pathogens in a single 
therapy have already been conducted by developing multispecific-T cells for 
adoptive transfer (LEEN et al., 2006; PAPADOPOULOU et al., 2014). Since 
prophylactic application of adoptive T cell therapy is logistically challenging and 
may not be easy to implement in large patient cohorts, it would be much more 
beneficial if a vaccine was developed that is able to control multiple harmful and 
life-threatening infectious agents in patients undergoing transplantations.  
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VI. SUMMARY 
Human cytomegalovirus (HCMV) is a member of the -Herpesvirinae subfamily 
and plays an important role in transplant recipients and infected newborns 
because primary infection and reactivation of HCMV cause lifelong problems and 
require expensive and harmful treatment. This constitutes an even greater 
problem as seroprevalence of human cytomegalovirus (HCMV) ranges between 
30 and 90% in the human population. Despite huge efforts in the development of 
a satisfying vaccine against HCMV in the last decades, not a single vaccine 
candidate has been successfully evaluated until now. 
Live attenuated Modified Vaccinia virus Ankara (MVA) is one of the most 
promising viral vector systems as it is replication deficient in human cells but 
efficiently delivers recombinant proteins encoded by heterologous genes. 
Thereby, MVA enables the induction of cellular immune responses and humoral 
ones. Moreover, large scale production of recombinant MVAs is feasible under 
GMP conditions. Hence, MVA meets several important requirements for the 
production of an adequate vaccine.  
Within this study, a recently constructed HCMV vaccine candidate 
(MVA-pp65/IE-1) based on MVA was characterized genetically and 
immunologically. CD40 B cells infected with recombinant MVAs were established 
as a valuable tool for immunological characterization of recombinant 
HCMV-MVAs. By growth kinetics, replication deficiency of MVA-pp65/IE-1 was 
proven in mammalian cells (HaCaT) and replication competence was shown in 
primary chicken embryo cells (CEF). A 120 kDa protein that was expressed in 
MVA-pp65/IE-1-infected cells was recognized by HCMV-specific antibodies. 
Antigen-specific T cells to various epitopes of IE-1 and pp65 were expandable in 
vitro by stimulation with MVA-pp65/IE-1-infected B cells. Furthermore, functional 
T cell responses to various IE-1 peptides of IE-1-specific T cells were detected by 
IFN-  measurement. 
These data indicate that MVA-pp65/IE-1 meets important requirements as 
vaccine against HCMV. Thus, subsequent studies focusing on the further 
development of this promising vaccine candidate should be aspired. 
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VII.  ZUSAMMENFASSUNG 
Das humane Zytomegalievirus (HCMV) gehört zur Unterfamilie der 
-Herpesvirinae und spielt vor allem in Transplantationsempfängern und 
infizierten Neugeborenen eine bedeutende Rolle, da Primärinfektionen oder 
Reaktivierungen mit HCMV ein lebenslanges Leiden verursachen, welches 
lediglich mit teuren und schädlichen Medikamenten behandelt werden kann. Dies 
stellt ein besonders großes Problem dar, da die Seroprävalenz von HCMV 
innerhalb der menschlichen Bevölkerung zwischen 30 und 90% beträgt. Obwohl 
bereits seit Jahrzenten an der Entwicklung eines wirksamen Impfstoffes gegen 
HCMV geforscht wird, konnte bisher kein einziger Impfstoff erfolgreich getestet 
werden.  
Das Modifizierte Vacciniavirus Ankara (MVA) gilt aufgrund seiner besonderen 
Eigenschaften als eines der vielversprechendsten viralen Vektorsysteme für 
Impfstoffe, da es zwar in menschlichen Zellen nicht repliziert, aber auf effiziente 
Art und Weise rekombinante Proteine exprimieren kann, die durch heterologe 
Gene kodiert werden. Dies ermöglicht sowohl die Induktion der zellulären als 
auch der humoralen Immunantwort. Ein weiterer Vorteil des MVA Vektorsystems 
besteht darin, dass die Viren in großen Mengen und unter GMP Bedingungen 
hergestellt werden können. Hiermit erfüllt MVA wichtige Voraussetzungen für die 
Herstellung eines erfolgreichen Impfstoffes.  
Diese Arbeit beschreibt die genetische und immunologische Charakterisierung 
eines neuen auf der Basis von MVA entwickelten Impfstoffkandidaten gegen 
HCMV (MVA-pp65/IE-1). Dabei wurde die Infektion von CD40 B Zellen mit 
rekombinanten MVA Viren etabliert und zur immunologischen Charakterisierung 
dieser Viren verwendet.  
Das rekombinante Virus MVA-pp65/IE-1 war in primären Hühner-
embryofibroblasten (CEF) vermehrungsfähig, nicht aber in humanen Zellen 
(HaCaT). Ein 120 kDa großes Protein konnte in MVA-pp65/IE-1 infizierten Zellen 
exprimiert und durch HCMV-spezifischen Antikörper nachgewiesen werden. Mit 
MVA-pp65/IE-1 infizierten B Zellen war es möglich, T Zellen spezifisch gegen 
eine Vielzahl von IE-1 und pp65 Epitopen zu expandieren. Hierbei konnte zudem 
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eine funktionelle T Zellantwort gegen eine Vielzahl von verschiedenen IE-1 
Peptiden durch IFN- -Messung gezeigt werden. 
Diese Ergebnisse zeigen erstmals, dass MVA-pp65/IE-1 wichtige 
Voraussetzungen als Impfvirus gegen HCMV erfüllt. Daher ist eine 
weitergehende Erforschung und Entwicklung dieses vielversprechenden 
Impfstoffkandidaten anzustreben. 
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IX. APPENDICES 
1. Buffers, solutions, and SDS-gel 
Buffers and solutions Conditions 
Loading buffer (6 ) 10 mM Tris-HCl pH 7,6 
0.03% bromophenol blue 
60% glycerol 
60 mM EDTA 
add. distilled water 
Lysis buffer (1 ) 62.5 mM Tris-HCl pH 6,8 
2% SDS 
10% glycerol 
50 mM DTT 
0.01% bromophenol blue 
add. distilled water 
PBS (1 , pH 7.4) 140 mM NaCl 
KCl 
Na2HPO4 + 7H2O 
KH2PO4 
add. distilled water 
TAE (50 . pH 7.8) 2 M Tris-acetate 
0.5 M NaCl 
50 mM EDTA 
add. distilled water 
TBS (10 , pH 7,6) 200 mM Tris base 
1.4 M NaCl 
add. distilled water 
Transfer buffer (1 ) 25 mM Tris base 
200 mM glycine 
20% ethanol 
add. distilled water 
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SDS-gel Conditions 
Resolving gel (10%) 
 
9.9 ml (30% acrylamide) 
7.5 ml (1.5 M Tris-HCl pH 8.8) 
0.15 ml (20% SDS) 
0.9 ml (10% ammoniumpersulfate) 
24 µl TEMED 
add. 30 ml distilled water 
Stacking gel (5%) 1.5 ml (1.0 M Tris-HCl pH 6.8) 
45 µl (20% SDS) 
0.27 ml (10% ammoniumpersulfate) 
18 µl TEMED 
add. 9 ml distilled water 
 
2. Commercial kits 
Commercial kits Supplier 
AP Conjugate Substrate Kit Bio-Rad, München, Germany 
Clarity™ ECL Western Blotting 
Substrate 
Bio-Rad, München, Germany 
EnzygnostR Anti-CMV/IgG Siemens, Erlangen, Germany 
Human IFN-  ELISA Kit (ALP)  Mabtech, Nacka Strand, Sweden 
Human IFN-  ELISPOT Kit (ALP)  Mabtech, Nacka Strand, Sweden 
Trans-Blot Turbo Mini Nitrocellulose 
Transfer pack 
Bio-Rad, München, Germany 
 
3. Media and additives 
Media and additives Supplier 
HEPES Buffer (1 M) Sigma-Aldrich, St.Louis, USA  
Fetal calf serum (FCS) Gibco Invitrogen, Karlsruhe, Germany 
MEM Non-Essential Amino Acid 
Solution (100 ) Sigma-Aldrich, St.Louis, USA 
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Minimum Essential Medium Eagle 
(MEM) 
Sigma-Aldrich, St.Louis, USA 
PBS Dulbecco (w/o Mg2+) PAN Biotech, Aidenbach, Germany 
Penicillin (10,000U/ml)/ 
Streptomycin (10mg/ml) 
Sigma-Aldrich, St.Louis, USA 
RPMI-1640 Gibco Invitrogen, Karlsruhe, Germany  
Sodium selenite ICN Biochemicals, Aurora, USA 
Trypsin-EDTA solution Sigma-Aldrich, St.Louis, USA 
Gibco Invitrogen, Karlsruhe, Germany 
VLE Dulbecco’s MEM (DMEM) Merck Millipore, Biochrom GmbH 
 
4. Laboratory equipment and software 
  
Laboratory equipment Supplier 
Avanti® J-26 XP Centrifuge Beckman Coulter, Krefeld, Germany 
ChemiDocTMMP, Imaging System Bio-Rad, München, Germany 
EL800, Universal Microplate Reader BIO TEK Instruments, Winooski, USA 
FACS Calibur cytofluorometer Becton Dickinson, Heidelberg, 
Germany 
ImmunoSpot 5.0 Analyzer ProCD C.T.L., Shaker Heights, USA 
Irradiation device Gammacell 40 
(Cs-137) 
Atomic Energy of Canada Limited, 
Ottawa, Kanada 
Mupid®-One electrophoresis system Mupid CO. LTD, Tokyo, Japan 
Neubauer counting chamber Paul Marienfeld, Lauda-Königshofen, 
Germany 
PeqSTAR 2X Thermocycler PEQLAB, Erlangen, Germany 
Power Ease 500 protein 
electrophoresis 
Invitrogen life technologies, Carlsbad, 
USA 
OptimaTMLE-80K Ultracentrifuge Beckman Coulter, Krefeld, Germany 
Sonoplus Bandelin electronic, Berlin, Germany 
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Software Supplier 
NCBI BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
CellQuestTM Pro Software  BD Biosciences, Heidelberg, Germany 
CTL ImmunoSpot Software C.T.L., Shaker Heights, USA 
KC4 BIO TEK Instruments, Winooski, USA 
Image Lab 5.0 Software Bio-Rad, München, Germany 
Prism 5  GraphPad Software, La Jolla, USA 
 
5. Reagents, materials, and chemicals 
Reagents/materials/chemicals Supplier 
Acetic acid (C2H4O2) Carl-Roth GmbH, Karlsruhe, Germany 
Acrylamide 30% (C3H5NO) AppliChem, Darmstadt, Germany 
Ammoniumpersulfate (H8N2O8S2) AppliChem, Darmstadt, Germany 
Biozym LE Agarose  Biozym, Hessisch Oldendorf, Germany 
Bovine serum albumine (BSA) Sigma-Aldrich, St.Louis, USA 
Bromophenol blue Merck, Darmstadt, Germany 
CpG-A (ODN 2216) Miltenyi, Bergisch-Gladbach, Germany 
CpG-B (ODN 2006) Metabion, Planegg, Germany 
Cyclosporin A Novartis, Nürnberg, Germany 
Distilled water In-house production, München, Germany 
DMSO (C2H6OS) Carl-Roth GmbH, Karlsruhe, Germany 
DTT (C4H10O2S2) Sigma-Aldrich, St.Louis, USA 
EDTA (C10H16N2O8) ICN Biomedicals, Ohio, USA 
FACS Flow/Clean/Rinse BD Bioscienes, Heidelberg, Germany 
Geld RedTM Biotrend, Köln, Germany 
Glycerol (C3H8O3) Carl-Roth GmbH, Karlsruhe, Germany 
Glycine (C2H5NO2) Carl-Roth GmbH, Karlsruhe, Germany 
Hydrochloric acid (6 N,HCl) Carl-Roth GmbH, Karlsruhe, Germany 
Immunoplates MaxiSorp® 96-well flat 
bottom 
Nunc A/S, Roskilde, Denmark 
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Monopotassium phosphate (KH2PO4) Carl-Roth GmbH, Karlsruhe, Germany 
 
HTS-HA (MSHAN4510) 96-well 
Millipore, Billerica, USA 
Nonfat dried milk powder AppliChem, Darmstadt, Germany 
Pathogen-free chicken eggs Charles River Laboratories, 
Massachusetts, USA ; 
VALO Biomedia GmbH, Osterholz-
Scharmbeck, Germany 
Para-nitrophenyl phosphate (p-NPP) Carl-Roth GmbH, Karlsruhe, Germany 
Potassium chloride (KCl) Merck, Darmstadt, Germany 
Precision Dual Color protein ladder  Bio-Rad, München, Germany 
ProtranTM AmershamTM Nitrocellulose 
membrane, 0.2 µm  
GE Healthcare, München, Germany 
Pro5 Fluorotag-PE Proimmune, Oxford, UK 
Recombinant human interleukin-2(rhIL-
2) 
Novartis, Nürnberg, Germany 
Ready to use DNA standard  Thermo Fisher Scientific, Massachusetts, 
USA 
SDS (C12H25NaO4S) Carl-Roth GmbH, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl-Roth GmbH, Karlsruhe, Germany 
Sodium Monohydrogen Phosphate 
Heptahydrate (Na2HPO4 + 7H2O) 
Carl-Roth GmbH, Karlsruhe, Germany 
TEMED (C6H16N2) Sigma-Aldrich, St.Louis, USA 
Tris-glycine buffer (10 ) Bio-Rad, München, Germany 
Tris-ultrapure (C4H11NO3)  AppliChem, Darmstadt, Germany 
Trypan blue Sigma-Aldrich, St.Louis, USA-Aldrich 
Merck, Darmstadt, Germany 
Tween20 Sigma-Aldrich, St.Louis, USA-Aldrich 
4-20% Criterion TGX stain free gel  Bio-Rad, München, Germany 
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Other plasticware  
(plates/flasks) used for Supplier 
CD40 B cells, polyclonal T cell lines, and 
Immunological assays 
 
6-/12-/24-/48-/96-well flat bottom plates BD Bioscienes, Heidelberg, Germany 
Cell culture flasks (25/80/175 cm2) Nunc A/S, Roskilde, Denmark 
Viruses, PCR, and Western blot   
6-/12-/24-/96-well flat bottom plates Sarstedt, Nümbrecht, Germany 
Cell culture flasks (75/175 cm2) Sarstedt, Nümbrecht, Germany 
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